I am Associate Professor of Cardiovascular Medicine at the

Prof. Flavio Luciano Ribichini

Curriculum vitae:

Scientific, teaching and clinical activity.

December 2015

A first acknowledgement:

In general, a CV is a formal list of actions performed during the professional life and perceived by the candidate as important and fair and as such, deserving to be mentioned. These are publically declared in order to be known and acknowledged by others, as requested by the parameters of evaluation of our society.

A CV however, never reports on the mistakes, or on the persons that have helped us to achieve those objectives that we boast. These persons are mentioned in this document as an acknowledgement of my gratitude.

Making it clear that I have learnt more from the mistakes than form success, and that I am in debt with those who supported me and gave me the opportunity to show what I can be able to do, I declare the following:

I was born in Còrdoba, Argentina, on May 28th 1963. I married (only once) Valeria, who is the mother of my three kids who, (fortunately) look as beautiful as their mum.

Present position and general activities

I am Associate Professor of Cardiovascular Medicine at the University of Verona , and I obtained the degree of “Full Professor of Cardiovascular Medicine” according to the resolution of the National Ministry of Education in December 2013.

I teach at the School of Medicine of the Univeristy of Verona at different courses, medical students, nurses, physiotherapists, residents of the School of Cardiology and PhD students.

The direct phone number of the University line to get in contact with me is +39 045 812 2039.

I am the director of the Cardiovascular Interventional Unit of the University Hospital in

Verona (known as “Azienda Ospedaliera-Universitaria Integrata di Verona (AOUI).

The address of the AOUI di Verona is, Piazzale Aristide Stefani 1, 37128, Verona. (Secretary phone numbers 045 812 2320/2077). The Director of the Division of Cardiology, and Head of the

Cardiovascular Department to which I report is Prof. Corrado Vassanelli, my chief and mentor.

I am also Director of the PhD School of Life and Health Sciences of the University of Verona.

Strada delle Grazie 8. 37135- Verona.

Segreteria: Laura Marcazzan, Telefono: 045 802 7026. E-mail: laura marcazzan univr it

A glance to the activity of the Cardiovascular Interventional Unit of our center:

In brief, We (intended my wife, my daughter and myself) moved to Verona in April 2006.

At that time we had only one daughter, and then we were blessed with the birth of other two kids.

After nearly ten years of work in Verona I am proud to say that the activity of the Cardiovascular

Interventional Unit of our Center is one the most lively and prestigious in our Country, ranked among the top Interventional Units in Europe. Indeed, the Cardiovascular Interventional Unit of

Verona has achieved several objective goals in the last years that are unique to very few centers in

Italy and that witness the high professional level reached in our Institution.

In fact, Verona has been the Coordinating center of the National Multicenter

“Executive Trial”

. It is the “top enrolling” center in the International,

Randomized EXCEL study , the largest study ever performed comparing coronary angioplasty and cardiac bypass surgery for the treatment of left main disease , the most severe form of coronary artery disease. In July 2015, our Institution performed the first transplantation of autologous bone marrow stamina cells for the treatment of heart failure in the context of the International Randomized CHART-1 Clinical Trial . Verona, being the only Italian center approved to perform such innovative study by the Ministry of Health, is the only Italian center running a controlled study on stamina cells transplantation for heart failure.

Since 2013, our Institution is the ONLY accredited facility performing a regular activity on sympathetic renal denervation according to a monitored program under the quality assessment of the Regional Office of Public Health, with more than 20 cases successfully treated so far.

Apart from these international studies, the “school of cardiology” of Verona is faithful to its heritage of education and research and has promoted many independent studies that have been presented in the most important international scientific meetings, have received international awards and have been published in the world top-class scientific journals. Currently, Verona is the Italian

Coordinating center of FDA-regulated studies dedicated to physiologically-guided surgical or percutaneous revascularization procedures, like the FDA registered GRAFFITI and ADVISE-

FLAIR randomized trials. Furthermore, we are conducting independent National studies on the assessment of the bioresorbable stent technology with the ABSORB scaffold in heart transplanted patients ( CART Trial) and in patients with diffuse coronary artery disease ( IT DISAPPEARS ,

Nationwide Italian Registry on BVS in diffuse CAD).

Of note, in 2015 Verona has reached the highest volume of trans-catheter aortic valve implantation

( TAVI) in the Regione Veneto (more than 70 cases in 2015). On this specific field, the Division of

Cardiology closely cooperates with a Regional program of heath technology assessment and quality control of clinical outcomes.

Our Interventional Unit receives over 2000 patients each year. It is a teaching institution for specialists interested in different branches on the endovascular medicine, and the clinical activity performed in our Institution makes of it one of the most eclectic and comprehensive, with active programs on structural heart disease, renal denervation, coronary and peripheral angioplasty, and a

24h day hub emergency service for primary PCI and emergency treatment with left ventricular assistance devices for patients with cardiogenic shock and acute valvular pathologies unique in the whole Province of Verona. Of note, the renal denervation program running in our hospital is inserted in the context of the International Global Symplicity Registry and is the only renal denervation program active in the whole Veneto Region in cooperation with the Veneto heath technology assessment agency.

The continuously growing activity in the field of medical care, education and research is supported by the dedication of our team and by my personal participation at the Advisory Boards of the major multi-national manufacturing companies in the field such as, Abbott, Medtronic, Boston Scientific,

Edwards, Volcano, Abiomed and Sorin to which I cooperate with on the design and development of new technologies, clinical studies and medical care policy. Similarly, I actively contribute to the

Editorial Boards of the major scientific cardio-vascular Journals either as a member of the Editorial

Boards, or as a scientific reviewer. I am also member of the Scientific Committees of the mayor

International events such as PCR, TCT, Russia TCT, EMICS, Tech Exchange, among others.

The future:

The future of the Cardiology of Verona looks even more promising than its present, since many young fellows complete their training started in Verona at the most prestigious Institutions in the world thanks to the cooperative programs of continuous education and research established in these years with foreign “first-class” centers such as the University of Oxford, UK, the Montreal Heart

Institute, Canada, the Istituto Dante Pazzanese di Sao Paulo Brazil for pediatric cardiology, the

OLVZ-Cardiovascular Center in Aalst, Belgium, the Royal Bromptom Hospital in London, the

Charles University of Prague, Czech Republic, among others.

Research fields

Along my career I have been strongly committed to education of fellows and research. I have been involved in different aspects of the vascular pathology, both in the coronary and peripheral districts harmonizing studies of basic and experimental science, physiopathology and clinical cardiology.

I have had the privilege of taking part of the American and European Task Forces dedicated to the release of International Guidelines. In 2000 I contributed to the AHA (American Heart Association) for the preparation of the Cardio-Pulmonary Resuscitation Guidelines (CPR American Heart

Association 2000) and in 2010 with the European Society of Cardiology for design of the very first version of the Myocardial Revascularization Guidelines, and in 2015 I have been appointed to the

European Task Force of the European Society of Cardiology for the treatment of acute ischemic stroke.

In particular, the following areas of research have been objective of publication in journals of high scientific impact:

1.

Treatment of acute myocardial infarction with primary angioplasty, and in particular, the performance of primary angioplasty without surgical back-up on site.

2.

Genetics of restenosis after angioplasty

3.

Genetics of coronary artery disease in the young.

4.

Systemic immunosuppressive therapy as anti-restenotic and anti-atherosclerotic treatment in animals and in humans.

5.

In-vivo histologic studies of the atherosclerotic plaque.

6.

The role of the renin-angiotensin system in the mechanisms of plaque progression and restenosis.

7.

Diagnostic (invasive and non-invasive) aspects of aortic valve stenosis.

8.

The multi-level vascular disease, concomitant coronary and carotid atherosclerosis.

9.

Cardiac structural defects and cryptogenic ictus in the young and associations between acute coronary and cerebrovascular syndromes.

10.

Hemodynamic and echographic diagnosis of aortic valve stenosis and trans-catheter treatment in the elderly at high surgical risk.

11.

Intravascular ultrasound and late stent thrombosis.

12.

Physiologic assessment of coronary artery disease, hyperhemic and resting gradients.

13.

Kidney disease associated to coronary artery disease and contrast-induced nephropathy.

14.

Complex coronary percutaneous interventions in multi-vessel disease, and left ventricular hemodynamic support.

15.

Renal sympathetic denervation in patients with resistant hypertension.

The results of 20 years of continuative research work are witnessed in the list of almost 200 publications reported at the end of this document, with an Impact Factor of 1030, with 7490 citations (according to Scopus). H index (Hirsch Index) 33 (source Scopus, articles published since

1992).

Furthermore, I have lectured on nearly 300 scientific meetings all around the world as detailed below.

To get in contact:

Although it is easy to contact me through the secretaries or directly through my email, I am actually quite reticent to answer the phone. This is because I am often out of town for travels and when on site, I spend most of my time in the operating rooms where I cannot get phone calls.

The best way to contact me then is an email to flavio.ribichini@univr.it

.

For those interested on more details about my professional activities, please read the next 60 pages of this CV and do not hesitate to contact me directly if you want to discuss on a research project, a teaching initiative, if you have a challenging clinical case to share, or if you just need an opinion on a difficult case.

Education

1976-1980 Scientific High School "Dean Gregorio Funes", Còrdoba, Argentina (the same where Ernesto Guevara de la Serna was a student).

1981-1986 Degree in Medicine and Surgery, Universidad Nacional de Còrdoba, Argentina.

Degree on December 1986.

1986-1988

1988-1989

Internal Medicine training. Centro Medico HP, Còrdoba, Argentina.

Fellow of the Italian Ministry of Health at the Department of Biomedical

Science of the University of Torino, Italy

1989

1989-1992

Degree in Medicine and Surgery, University of Torino

Board in Cardiology, School of Cardiology, University of Torino.

Training and professional experience.

I performed my fist coronary angiogram in 1989 when I was a fellow in training at the School of

Cardiology of the University of Turin, in North-West Italy.

Then I had the opportunity of training hard on diagnostic angio and assisting on the firsts coronary angioplasties at the Cardiology Division of the Ospedale Multizonale di Circolo di Varese E.

Macchi in 1991, when coronary stents where still not available!

But I learnt the essential tricks of PTCA (as performed in those heroic times) from Paul Barragan and Marc Silvestri in Marseille, France in the spring of 1993. In the meantime, I was a staff member of the Division of Cardiology of the Ospedale Santa Croce in Cuneo directed by Prof. Eugenio

Uslenghi. Cuneo is a small city in the alpine region of north-west Italy where we developed, in the early nineties, a pioneering program of primary angioplasty in acute myocardial infarction. This was actually the first organized emergency angioplasty service in Italy without cardiac surgery on site, and for many years served as a model for many other centers that started their activity following our experience. During these ten years in Cuneo (1991-2002), I performed about 1500 coronary interventions, and over 5000 diagnostic catheterizations, but most important, I had the opportunity of training and studying abroad in different prestigious academic centers, such as the

Hopital Henri Mondor, Universitè de Paris, Creteil, France in 1994 with Prof. Herbert Geshwint and

Prof. J.L Dubois Rande. In 1995 at the Center for Research in Cardiovascular Interventions della

Stanford University School of Medicine, California USA with Dr. Steve Oesterle, Paul Yock and

Peter Fitzgerald. In 1996 at the Cardiovascular Institute of the Mount Sinai Medical Center, New

York, with Prof. John Ambrose. In 1997-1998 I was awarded a Research Fellowship of the

European Society of Cardiology and worked at the Cardiovascular Center of the OLV Hospital in

Aalst, Belgium, with Dr. William Wijns and Bernard DeBruyne. Finally in 2000 I spent a brief studying period at the Institute of Cardiovascular Pathology of the Armed Force Institute of

Pathology (AFIP), Washington DC with Dr. Renu Virmani.

In March 2002 professor Corrado Vassanelli offered me the possibility of starting an academic career as Assistant Professor of the School of Medicine of the University of Piemonte Orientale in

Novara and in my early forties I got my first appointment as Director of the Interventional

Cardiovascular Unit of the Ospedale Maggiore di Novara. During this period I started my academic

experience as a teacher at the School of Medicine and performed 1800 cardiac catheterizations and

760 coronary interventions, and after 4 years of activity we both moved to the University of Verona.

Since March 2006 I am the Director of the Cardiovascular Interventional Unit of the AOUI in

Verona, and since December 2006, Associate Professor of Cardiovascular Medicine. I am also consultant for the Divisions of Cardiac Surgery and the General Intensive Care Unit of the hospital.

Languages

As I said before, I was born in Argentina where I got my first medical degree, therefore Spanish is my first language. Then after many years of leaving in Europe and travelling around the occidental world, I got to know some other languages at a decent level such as:

Italian, level: good

English, level: good

Spanish, level: good

French, level: good

Portoghese, level: good

Table showing the scientific pubblications with IF.

Rivista

American Heart Journal

American Journal of Cardiology

American Journal of Medicine

Annals of Emergency Medicine

Archives of Medical Research

Arteriosclerosis Thrombosis & Vascular Biology

Artificial Organs

Atherosclerosis

British Heart Journal (Heart)

British Journal of Pharmacology

British Journal of Radiology

Cardiologia

Cardiology in the Young

Cardiovascular Revascularization Medicine

Catheterization and Cardiovascular Interventions

Cellular Physiology and Biochemistry

Chest

Circulation

Circulation Cardiovasc Intervention

Clinical Chemestry

Clinical Nuclear Medicine

Clinical Science

Coronary Artery Disease

Diabetes Care

Drugs

Endocrinology

European Heart Journal

Eur Journal of Cardiothoracic Surgery

Eurointervention

Experimental Physiology

Giornale Italiano di Cardiologia

Heart

Hypertension

International Journal of Cardiology

International Journal of Cardiovascular Imaging

Italian Heart Journal (J Cardiovasc Med)

Interactive Cardiovascular Thoracic Surgery

Journal of American College of Cardiology

JACC Cardiovascular Interventions

Journal of American Medical Association

Journal of Cardiovascular Medicine

Journal of Cardiovascular Translational Research

Journal of Endovascular Therapy

Journal of Interventional Cardiology

Journal of Invasive Cardiology

Journal of Nephrology

Journal of Nuclear Cardiology

Journal of Pharmacology & Experimental Therapeutics

Journal of Thoracic and Cardiovascular Surgery

5

2

8

1

2

2

1

1

2

1

16

4

1

4

1

1

1

1

3

1

6

5

1

7

2

1

4

1

6

Numero dei lavori pubblicati

4

9

3

1

1

1

1

2

1

6

4

1

1

5

1

2

2

6

1

1

Impact Factor nel 2013

4.555

3.425

5.302

4.333

2.406

6.338

6.175

2.322

1.407

1.109

15.343

7.44

30.387

1,407

2.691

3.59

8.57

4,133

4.717

14,723

2.814

3.758

2.871

1.407

6.023

7.632

1.318

0.824

1.996

2.645

3.855

3.991

0.646

2.396

3.55

7.132

14.948

6.982

7.768

2.857

5.629

1.302

1.87

3.706

6.023

4.99

1.533

1.407

0.857

Impact Factor

Complessivo

18.225

30.825

15.906

4.333

2.406

6.338

24.7

2.322

5.628

1.109

92.058

37.2

30.387

9.849

5.382

3.59

8.57

8.266

4.717

73.615

5.628

30.064

2.871

22.512

24.092

7.632

3.954

0.824

11.976

2.645

3.855

3.991

1.87

18.530

6.023

9.98

1.533

2.814

0.857

3.876

9.584

3.55

14.264

89.688

6.982

7.768

5.714

11.258

1.302

Journal of Thrombosis and Haemostasis

Journal of Vascular Research

Kidney International

Lancet

Medical Science Monitor

Minerva Medica

Nature Genetics

Nephrology Dialysis Transplantation

Nuclear Medicine Communications

PLoS One

Progress in Cardiovascular Disease

TOTALE

1

157

Valore medio (arrotondato)

(Updated to December 2014)

Cooperation with scientific journals

Member of the Editorial board:


Giornale Italiano di Cardiologia Interventistica

Journal of the Argentine College of Intervetional Cardiology

Seminars in Cardiovascular Medicine

Heart Blood and Vessels

Scientific Reviewer:

1

1

2

1

1

1

1

1

2

1

American Heart Journal

American Journal of Cardiology

American Journal of Medicine

Atherosclerosis

Cardiovascular Revascularization Medicine

Catheterization and Cardivascular Interventions

5.55

2.433

8.52

39.207

1.216

1.202

29.973

3.488

1.371

3.534

2.443

5.3

5.55

2.433

8.52

39.207

1.216

1.202

59.946

3.488

2.742

3.534

2.443

828.303

Circulation

Clinical Chemistry

Drugs

Eurointervention


Heart

International Journal of Cardiology

Journal of Cardiovascular Medicine

Journal of Clinical Pharmacology

Journal of Haemostasia and Thrombosis

Journal of Interventional Cardiology

Journal of the American College of Cardiology

Journal of Nephrology

The Lancet

Thrombosis and Vascular Biology

Chapters in books

Editor of the web-based e-book: Trattamento della Malattia Carotidea. Prous Science, Barcelona

2008.

Pharmacology in the Catheterization Laboratory. Willey Blackwell, NJ US 2010. ISBN 978-1-

4051-5704-9. Autore del capitolo “ Systemic Pharmacotherapy for In-stent Restenosis.

Endovascular Surgery for Congenital and Acquired Heart Disease. Edito da Bokeria & B. G.

Alekian. Moscow 2008. Autore del Capitolo 14, Vol 1: Atherosclerosis. Basis of Medical Therapy for the Intervetionalist.

Percutaneous Interventional Cardiovascular Medicine Textbook. Europa Edition, Toulouse, France

2012. ISBN, 978-2-913628-57. Autore del capitolo: Interventions for Patients with Chronic Renal

Disease.

Endovascular Surgery for Congenital and Acquired Heart Disease. Editon, Bokeria & B. G.

Alekian. Moscow 2016. Autore del Capitolo 8, Vol 1: Atherosclerosis. Basis of Medical Therapy for Interventionalists


Alekian. Moscow 2016. Autore del Capitolo 14, Vol 1: Kidney Disease and Coronary Interventions.


Alekian. Moscow 2016. Autore del Capitolo 14, Vol 1: The need for emergency surgical stand-by in intervetional cardiology.

Seminars, Conferences and Lectures at National and International Scientific Meetings

1994-95

1. 68th Annual Scientific Meeting of the American Heart Association. Anaheim, USA. November

13-16 1995. Speaker.

2. XVIII Congresso nazionale del gruppo italiano di studi emodinamici e cardiologia interventisitca,

Vicenza 5-7 ottobre 1995. Relatore.

3. V Giornate Cardiologiche. Cuneo, 7 Ottobre 1995. Relatore invitato.

4. 17th Congress of the European Society of Cardiology. Amsterdam, 19-24 August 1995. Speaker.

5. XXVI Congress of the Italian Society of Cardiology (ANMCO). Florence, Italy. June 4-7, 1995.

Speaker.

6. Jornadas de actualizacion medica. Fundaciòn Vida. Salta, Argentina, 20 dicembre 1994. Invited speaker. La angioplastia con stent itracoronario.

7. XXI Congresso de la Sociedad Argentina de Medicina. Buenos Aires, Argentina, 21-25

Novembre 1995. Invited speaker. La Red del tratamiento del infarto agudo.

8. Symposium New trends in PTCA. Torino, 7 Maggio 1994. Invited speaker: L’angioplastica coronarica senza stad-by cardiochirurgico

1996

9. 69th Annual Scientific Meeting of the American Heart Association. New Orleans, USA.

November 10-13 1996. Speaker.

10. 30 Convegno Internazioinale di Cardiologia, Centro A. de Gasperis. Milano 22-27 Settembre

1996. Relatore Invitato.

11. 18th Congress of the European Society of Cardiology. Birmingam, UK. 25-29 August 1996.

Speaker.

12. XXVII Congress of the Italian Society of Cardiology (ANMCO). Florence, Italy. June 9-12,

1996. Speaker.

13. 45 Annual Scientific Session of the American College of Cardiology, Orlando, USA. March 24-

27 1996. Speaker.

14. Sophia Antipolis, European Heart House, 12-13-January 1996 First joint meeting of the national working groups on interventional cardiology, speaker.

1997:

15. “ACE e ACE –inibizione: nuove acquisizioni fisiopatologiche e nuove prospettive terapeutiche”. February 27, Cuneo (Italy).”Predisposizione genetica e malattia coronarica: ruolo del genotipo per l’ACE”: invited faculty (speaker);

16. Seminar on Cardiovascular Genetics. Ospedale San Raffaele, Milan, Italy. 17/04 1997. Invited

Speaker.

17. ANMCO “XXVIII Congresso Nazionale di Cardiologia”. June 1-4, Florence (Italy): invited faculty (speaker);

18. XIX ESC Congress 1997. August 24-28, Stockholm (Sweden): invited faculty (speaker);

19. “XIX Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 9-11,

Bologna (Italy): invited faculty (speaker);

20, 70th Annual Scientific Meeting of the American Heart Association. Orlando, USA. November

9-12 1997. Speaker.

21. 5 th

Joint Meeting of the Belgian and Dutch working groups on invasive cardiology. December 5,

Brussels (Belgium);

1998:

22. 17 th

Annual scientific meeting of the Belgian society of cardiology. February 5-7. 1998,

Brussels (Belgium); Invited Speaker. “Coronary Brachytherapy: a new alternative to prevent restenosis”.

23. Vascular and Myocardial aspects of ischemic heart disease. February 22-25, Lake Tahoe (U.S.);

24. Frontiers in Interventional Cardiology: Head to Toe Percutaneous Revascularization. February

25 – March 1, Houston (U.S.); Course.

25. Convegno Ipertensione Arteriosa e Cuore. Italian Society of Hypertension. Cuneo, Italy. 14/03

1998. Invited Speaker. Session: The Genetic of the RAS.

26. 47 th

Annual Scientific Session of the American College of Cardiology, Atlanta, USA. March

29, April 1 1998.Chairman of the Fireside Panel of the American College of Cardiology: Primary

Angioplasty: Where, How and When.

27. Congress of the Italian Society of Cardiology (ANMCO). Florence, Italy. 7-10 June 1998.

Chairman of the Session on Primary PTCA.

28. 20th Congress of the European Society of Cardiology. Vienna. Austria. 23-26/08 1998. Invited

Speaker, Session: Debate, Controversies in Coronay Stenting.

29. 32˚ Convegno Cardiologia “A. De gasperis”. September 21-25, Milan (Italy). “L’impiego dello stent può estenedere l’indicazione all’angioplastica coronarica nell’infarto acuto dopo trombolisi?”: invited faculty (speaker);

30. 2 nd International meeting on pathophysiology of stunning, hibernation and preconditioning.

October 15-17, Taormina (Italy): invited faculty (speaker);

31. 5th Heart Center Course on Coronary Stenting, Rotterdam The Netherland, December 10 1998.

Invited to perform a live demonstration case of intracoronary beta brachytherapy.

32. Symposium on Molecular Cardiology. Afligem, Belgium 14/12/1998. Invited Speaker.

33. 12th Annual Scientific Sessions of the Belgian and Dutch Working Groups on Invasive

Cardiology. Symposium on Intracoronary Brachytherapy. Zaventem, Belgium. 5-12-1998.

1999:

34. International Workshop: The dawn of a new era in the treatment of acute myocarial infarction.

January 29-30, Florence (Italy): invited faculty (speaker);

35. 5 th

International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. January 31 – February 2, Geneva (Switzerland): invited faculty (speaker);

36. 48 th

ACC congress. March 3-10, California (U.S.): invited faculty (panelist);

37. Genetica della malattia coronarica. Società Italiana di Ipertensione, 26/03/1999, Torino, Italy.

Faculty Member and speaker.

38. ANMCO “XXX Congresso Nazionale di Cardiologia”. May 30 – June 2, Florence (Italy): invited faculty (speaker); Symposium: Genetic bases of the myocardial infarction in the young.

Invited speaker.

39. 21th Congress of the European Society of Cardiology. Invited Speaker, Session: The Great

Debate, Strategies of reperfusion in Acute Myocardial Infarction. Barcelona, Spain, August 28,

September 1 1999.

40. Evidence-Based Conference of the American Heart Association for the Preparation of the

Guidelines for CPR 2000. Faculty and Invited Speaker. Dallas September 25-29 1999

41. “XX Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 23-25,

Palermo (Italy): invited faculty (speaker);

42. Itravascular radiotherapy. December 17, Bergamo (Italy): invited faculty (moderator);

2000:

43. International guidelines 2000 conference on CPR and ECC. Februrary 6-8, Dallas (U.S.).

“Acute Coronary Syndromes”: invited faculty (panelist);

44. 49 th

ACC congress. March 12-15, California (U.S.): invited faculty (panelist);

45. “XXI Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 23-25,

Palermo (Italy): invited faculty (speaker): Analisi Critica dei Trials con Inibitori delle

Glicoproteine.

46. Simposio de Instruccion en Resucitacion para America Latina de la American Heart

Association. Montevideo, Uruguay Dicembre 2000, invited speaker.

47. Training Programme on Endovascular Radiation Therapy for Restenosis Prevention. European

Society of Cardiology, Sophia Antipolis, 26-28 ottobre 2000, Invited speaker.

48. XXII Congress of the European Society of Cardiology, invited speaker, Hotline Sessions.

Amsterdam 26-30 August 2000: The Genetic of In-stent Restenosis. Results of the BetACE Trial

49. Washington, Armed Force Institute of Pathology (AFIP), Maggio 2000. Invited speaker: The angiographic presentation of restenosis. Clinical and prognostic implications.

50. Faculty e relatore invitato al DANAMI-2 meeting and meeting of the Scandinavian Society of

Cardiology. Arhus, Danimarca, 5-6 Maggio 2000.

51. Stanford University, California. Invited speaker. March 2000. Relazione: The role of ACE and

ACE-inhibition in vascular repair after percutaneous injury.

52. Scientific Sessions of the American College of Cardiology, New Orleans, March 2000.

Presenter.

2001:

53. 2 nd

International summit on acute cardiovascular care. January 31 – February 2, Aosta (Italy): invited faculty (speaker);

54. “XVI Giornate Cardiologiche Torinesi”. April 6-7, Turin (Italy). “Ruolo della farmacoterapia nella restenosi”: invited faculty (speaker);

55. Endocoronary Biomechanics and restenosis. April 6, Marseille (France). “Polyphormism I.D.

ACE and restenosis: invited faculty (speaker);

56. XVI Annual Meeting of the American Society of Hypertension, San Francisco 15-19

Maggio 2001. Presenter.

57. GISE - “Appropriatezza fattibilità e costo/utilità delle procedure diagnostiche e dei trattamenti nelle sindromi coronariche acute”. May 4, Bologna (Italy): invited faculty (speaker);

58. “Riunioni scientifiche regionali – SIC”. May 19, Genova (Italy). “L’analisi decisionale nella cardiopatia ischemica”: invited faculty (speaker);

59. International meeeting on vascular interventions. June 18-23, Positano (Italy): invited faculty

(speaker): “Primary angioplasty versus systemic thrombolysis”.

60. Forum question and answer dell’ANMCO sui trattamenti delle sindromi coronariche acute. Bari, settembre 2001. Invited speaker.

61. ESC Congress 2001. September 1 - September 5, Stockholm (Sweden): invited faculty

(speaker);

62. “II Congresso nazionale della società italiana di anatomia patologica e citopatologia diagnostica”. September 23-27, Turin (Italy).

63. Second Panafrican Course on Interventional Cardiology. October 5-6, Monastir (Tunisia.

“Direct PCI is the best treatment”: invited faculty (speaker);

64. First International PCI-AMI Meeting in Zurich. October 5-6, Zurich (Switzerland). “Can We define a common initial treatment strategy combining lytics and platelet inhibitors for all patients with AMI”: invited faculty (speaker);

65. Symposium on NSTEMI. The medical approach. Meeting of the Italian Society of Cardiology.

Novara 13 ottobre 2001, relatore invitato.

66. “Riunioni scientifiche regionali – SIC”. October 13, Genova (Italy). “L’analisi decisionale nella cardiopatia ischemica”: invited faculty (speaker);

67. “XXII Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 24-27,

Cernobbio (Italy): invited faculty (speaker);

68. Congress of the Italian Society of Cardiology (SIC). Interventional procedures with use of flow and pressure coronary wires transmitted to as live cases from the catheterization Laboratory of the

Ospedale Maggiore della Carita’ di Novara. Novara, 13 December 2001. Invited operator.

2002:

69. 8th International LDDR and Molecular Biology Course. Ginevra Switzerland 31/01-

02/02 2002. Faculty Member as invited speaker.

69. ANMCO “XXXIII Congresso Nazionale di Cardiologia”. May 18-22, Florence (Italy): invited faculty (speaker);

70. EuroPCR. May 21-24, Paris (France): invited faculty (speaker). Embolic Protection Systems in

Acute Myocardial Infarction” Acute Coronary Syndromes. May 22, Paris (France). “Embolic

Protection”: invited faculty (speaker);

71. 11 th Interventional Cardiology Symposium. June 5-7, Montreal (Canada): invited faculty

(speaker): primary Angioplasty versus Trombolysis.

72. ESC Congress 2004. August 31 - September 4, Berlin (Germany): invited faculty (speaker and

Chairman);

73. ESC Antithrombotic, Fibrinolytic and interventional treatment of unstable angina and MI.

October 17-19, Riga (Latvia). “Genetic risk factors for restenosis after coronary interventions”: invited faculty (speaker/moderator);

74. Third Panafrican Course on Interventional cardiology. October 3-5, Monastir (Tunisia.

“Phisyological assessment of vascular lesions. When and how?”: invited faculty (speaker);

75. “6˚ Corso di intervenzionistica cardiologica in Italia”. October 7-9, Novara (Italy). Co-director and live case operator.

76. “XXIII Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 23-26,

Verona (Italy): invited faculty (speaker); Istologia della aterosclerosi e della restenosi.

77. SIC “Aggiornamenti sul trattamento della patologia cardiovascolari”. November 8-9, Turin

(Italy). “Gli inibitori delle glicoproteine IIb/IIIa.”: invited faculty (speaker);

2003:

78. 9 th

International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. January 23-25, Geneva (Switzerland): invited faculty

(speaker);

79. Joint interventional meeting (JIM). February 13-15, Rome (Italy). “Overview of reperfusion treatment of AMI”: invited faculty (speaker);

80. “XVI Giornate Cardiologiche Torinesi”. April 11-12, Turin (Italy). “Gli stent medicati devono essere utilizzati in tutti i pazienti?”, “Ruolo degli ACE-inibitori”: invited faculty (speaker);

81. C-reactive protein, from pathophysiology to guidelines. July 7, Rome (Italy). “Steroids and restenosis”: invited faculty (speaker);

82. ESC Congress 2003. August 30 - September 3, Vienna (Austria): invited faculty (speaker);

83. CD rom invasive cardiology 2003, Gargonza, 3-5 ottobre 2004, relatore invitato.

84. SCIMAB Boston Scientific medical Advisory Board. November 6-7, Portofino (Italy).

“Indicazioni cliniche dei DES: must have and nice to have”: invited faculty (speaker);

85. Transcatheter Cardiovascular Therapeutics (TCT), September 15-19, Washington DC (U.S): invited faculty (speaker); The Inflammation Summit.

86. “7˚ Corso di intervenzionistica cardiologica in Italia”. October 3, Novara (Italy). Co-director and live case operator.

87. “Controversie nel trattamento della cardiopatia valvolare e dello scompenso cardiaco avanzato”.

October 10-11, Turin (Italy): invited faculty (speaker);

88. “XXIV Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 15-18,

Genova (Italy): invited faculty (speaker);

89. Fourth Pan African Course of Interventional Cardiology. Monastir, Tunis October 3-5

2003. Invited live transmission from Novara.

2004:

90. 10 th

International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. January 29-31, Geneva (Switzerland): invited faculty

(speaker);

91. Joint interventional meeting (JIM). February 12-14, Rome (Italy): invited faculty (chairman);

92. 3 rd

European conference on management of coronary heart disease. April 2-4, Nice (France).

Invited Speaker.

93. XV Giornate Cardiologiche Torinesi, Torino 20-23 Aprile, Relatore invitato.

94. “Corso di cardiologia ad impronta cardiochirurgica”. April 15, Novara (Italy): invited faculty

(speaker);

95. CD Rom Invasive cardiology. April 16-18, Mogliano Veneto, Treviso (Italy) Invited Speaker:

Complex PCI in Multi-vessel disease

96. Nuove Frontiere in Cardiologia Interventistica. Sesto San Giovanni, Milano, 4-5 giugno 2004. Relatore invitato.

97. EuroPCR. May 25-28, Paris (France): invited faculty (speaker);

98. “The 5 th

Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology. June 8-10, Moscow (Russia). “Acute coronary syndrome:using of dexamet-elutingstents – review of STRIDE and EMPEROR Trials.: invited faculty (speaker); and live case operator.

99. X SOLACI (Società Latino Americana de Cardiologia Invasiva) Devices Symposium. August 5,

Buenos Aires, Argentina. “DEXAMET: a steroid-eluting stent and DESIRE study”: invited faculty

(speaker);

100. ESC Congress 2004. August 28 - September 1, Munich (Germany): invited faculty (speaker);

101. Transcatheter Cardiovascular Therapeutics (TCT), September 27 - October 1, Washington DC

(U.S): invited faculty (speaker);

102 “XXV Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 6-9,

Napoli (Italy): invited faculty (speaker);

103. Riunione Regionale Scientifica della SIC. “Il cardiologo sul pianeta diabete”. October 16,

Turin (Italy). “Alternative agli stent medicati?”: invited faculty (speaker);

104. “65˚ Congresso Nazionale della Società Italiana di Cardiologia”. December 11-15, Rome

(Italy): invited faculty (speaker);

2005:

105. 11 th

International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. February 3-5, Geneva (Switzerland): invited faculty

(speaker);

106. Joint interventional meeting (JIM). February 17-19, Rome (Italy). “Overview of reperfusion treatment of AMI”: invited faculty (speaker);

107. 20 th Annual Interventional Cardiology International Symposium. March 20-25, Colorado

(U.S.). “Remaining space for oral drug in multi-vessel treatment”: invited faculty (speaker);

108. 3

3d

International summit on acute cardiovascular care. May 12-14, Venice (Italy): invited faculty (speaker);

109. EuroPCR. May 24-27, Paris (France): invited faculty (speaker);

110. “XXVI Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 15-18,


111. Sixth Panafrican Course on Interventional cardiology. September 29 - October 1, Monastir

(Tunisia. “Phisyological assessment of vascular lesions. When and how?”. Invited faculty (speaker);

112. XI CECI Interventional cardiology meeting- Otamendi Hospital LIVE demonstration course.

October 29-30, Buenos Aires (Argentina): invited faculty (speaker); “Oral Prednisione and

Atherosclerotic Disease”.

113. Transcatheter Cardiovascular Therapeutics (TCT), October 16-21, Washington DC (U.S): invited faculty (speaker);

114. Prevention of Restenosis. October 18, Washington DC (U.S.). “Role of inflammation in restenosis, and Utility of Anti-Inflammatory Compounds in Drug-Eluting Stents” : invited faculty

(speaker);

115. “Statine: una pillola per ogni stagione?”. November 19, Verona (Italy). “Statine e cuore: non e1 mai troppo presto: invited faculty (speaker);

116. “Update sulle sindromi coronariche acute”. December 17, Ascoli Piceno (Italy). “Istologia e fisiopatologia delle placche aterosclerotiche nelle sindromi coronariche acute”: invited faculty

(speaker);

2006:

117. 12 th


(speaker);

118. Joint interventional meeting (JIM). February 16-18, Rome (Italy): invited faculty (speaker);

119. TEP 2006 “Terapéutica Endovascular Percutanéa”. March 27-29, Buenos Aires (Argentina): invited faculty (speaker): The Evolution of Anti-coagulant and Anti-platelet therapy in

Interventional Cardiology”

120. Workshop TEAM: “Estrategias de reperfusión óptimas y modelos de organización asitencial en pacientes con infarto agudo de miocardio”, June 22-23, Vigo (Spain): invited faculty

(moderator);

121. SIC –Linee guida interventistica coronarica percutanea. July 8, Verona (Italy): invited faculty

(speaker);

122. “Una rete può salvare una vita: utilità di una rete territoriale per il trattamento dell’infarto acuto del miocardio”. September 23, Verona (Italy): invited faculty (speaker);

123. “Il trittico del cuore”. September 22-24, Verona (Italy): invited faculty (speaker);

124. Congresso della Socità Russa di Cardiologia Interentistica. Invited speaker and live case operator. Novosibirsk, Siberia, Russia, 29-30 Settembre 2006.

125. “XXVII Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 3-6,



127. “VIII giornata di cardiologia Interventistica Miranese”. November 18, Venice (Italy).

“Possibilita e limiti della rivascolarizzazione coronarica percutanea”: invited faculty (speaker);

128. “C’era una volta l’angina”. November 25, Verona (Italy). “Rivascolarizzazione, solo a pochi?”: invited faculty (speaker) ;

129. Abbott Crossroads – Complex lesions: Risk assessment and management. Brussels, December

1 st . Invited Lecturer: “The treatment of coronary bifurcations”.

2007:

130. High tech Marseille. January 24-26, Marseille (France): invited faculty (speaker);

131. 14 th


(speaker);

132. Joint interventional meeting (JIM). February 15-17, Rome (Italy): invited faculty (speaker);

133. TEP 2007 “Terapéutica Endovascular Percutanéa”. April 23-25, Buenos Aires (Argentina): invited faculty (speaker);

134. “Con il cervello e con il cuore”. May 19, Verona (Italy): invited faculty (speaker and chairman); La terapia anti-coagulante nelle sindromi coronariche e neurologiche acute.

135. EuroPCR. May 22-25, Barcelona (Spain): invited faculty (speaker);

136. The 9 th Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology. June 4-6, Moscow (Russia): invited faculty

(speaker) and live case operator.

137. 16 th

Interventional Cardiology Symposium. June 17-19, Montreal (Canada): invited faculty

(speaker); peripheral intervetions for cardiologists

138. 4 th

International summit on acute cardiovascular care. June 19-21, Verona (Italy): invited faculty (speaker);

139. Symposium “A step beyond in DES”. October 2-5, GISE Congress, Genova (Italy): invited faculty (speaker);

140. Critical issues in interventional cardiology. September 20, Munich (Germany): invited faculty

(workshop leader);

141. V Tyrolean Meeting, September 21-22. Bolzano (Italy): invited faculty (speaker);

142. “IX giornata di cardiologia Interventistica Miranese”. November 17, Venice (Italy): invited faculty (speaker); I sistemi di supporto emodinamico nella PCI complessa.

143. “Attualità e prospettive future del trattamento chirurgico ed endovascolare nei pazienti vasculopatici”. November 22, Verona (Italy): invited faculty (speaker)

2008:

144. IV Corso di specializzazione in emodinamica e cardiologia interventistica. February 5, Milano


145. 15 th


(speaker);

146. Joint interventional meeting (JIM), February 14-16, Rome (Italy): invited faculty (speaker);

147. III International course in prevention and treatment of complications in percutaneous interventional cardiology. February 28-29, Barcelona (Spain): invited faculty (speaker);

148. “III Convegno Cunesee di medicna nucleare”, April 5, Cuneo (Italy): La rivascolarizzazione miocardica nel paziente con insufficienza renale terminale.

149. “Incontri di Cardiologia del Triveneto: il trattamento della cardiopatia ischemica tra tecnologia, organizzazione sanitaria ed evidence-based medicine”, April 19, Verona (Italy): invited faculty (speaker);

150. EuroPCR, May 13-16, Barcelona (Spain): invited faculty (speaker);

151. Modern strategies in interventional cardiology, June 26-27, Aarhus (Denmark). Invited

Lecturer: From thrombolysis to PCI.

152 “Cardiologia oggi: esperienze a confronto”, September 20, Vercelli (Italy): invited faculty

(speaker); Lettura Magistrale: storia della riperfusione micardica.


154. “Il Paziente diabetico con cariopatia ischemica”, October 25, Verona (Italy): invited faculty

(speaker); La rivascolarizzazione del paziente diabetico.

155. Convegno Sda Bocconi “Tecnologie sanitarie e modelli di acquisizione pubblici per la salute”,

November 10, Milan (Italy): invited faculty (speaker);

156. “X giornata di cardiologia Interventistica Miranese”. November 15, Venice (Italy): invited faculty (speaker);

2009:

157. 16 th

International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”, February 5-7, Geneva (Switzerland): invited faculty

(speaker);


159. “ Dalla disfunzione ventricolare sinistra asintomatica allo scompenso cardiaco refrettario”.

March 21, Cuneo (Italy): invited faculty (speaker);

160. “Percorso diagnostico-terapeutici nella sindrome coronarica acuta”. April 23, Verona (Italy): invited faculty (speaker);

161. OCT, IVUS, FFR. When, where and how. Interactive course on intravascular imaging with minimally invasive approach. May 28-29, bergamo (Italy): invited faculty (speaker);

162. The 10 th

Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology. June 1-3, Moscow (Russia): invited faculty

(speaker and live case operator);

163. Italian forum on primary PCI. June 24, Milan (Italy): invited faculty (speaker);

164. ESC/EACTS Task Force Meeting on Myocardial Revascularization. July 6-7, Sophia Antipolis

(France): member.

165. “I a

Conferenza nazionale sulla trombolisi nell’ictus ischemico”. September 18-19, Verona


155. Transcatheter Cardiovascular Therapeutics (TCT). September 21-25, San Francisco (U.S): invited faculty (speaker);

156. “L’imaging nella diagnostica del cuore”. October 3, Verona (Italy) Speaker.

157. 5 th International summit on acute cardiovascular care. October 8-9, Verona (Italy): invited faculty (speaker);

158. “XXX Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 20-23,

Bologna (Italy): invited faculty (speaker);

159. “Meeting: “Nature of Superiority”. November 11, Moskow (Russia) invited faculty (Invited

Lecture);

160. “3˚ Corso di Interventistica Vascolare”. November 13-14, Palermo (Italy): invited faculty

(speaker); La malattia vascolare pluridistrettuale.

161. Working Group on Stent Evaluation and adoption. Munich December 9 2009. Chairman.



2010:


164. The 6 th

Belgrade Summit of Interventional Cardiologist plus. April 10-13, Belgrade (Serbia): invited faculty (speaker);

165. VII European Congress: Healthy and active ageing for all Europeans. April 14-17, Bologna

(Italy): invited faculty (speaker); TAVI: an emerging therapeutic option for the elderly patient with aortic stenosis.

166. IV International course in prevention and treatment of complications in percutaneous interventional cardiology. April 22-23, Barcelona (Spain): invited faculty (speaker);

167. “Stenting Carotideo: Indicazioni e risultati”. April 30, Rome (Italy);

168. EuroPCR, May 25-28, Paris (France): invited faculty (speaker);

169. The 11 th

Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology, June 6-9, Moscow (Russia): invited faculty

(speaker and live case operator);

170. 19 th

Interventional Cardiology Symposium. June 17-19, Montreal (Canada): invited faculty

(speaker); Immunosuppression to avoid stent Restenosis: The CEREA-DES study.

171. XVI SOLACI 2010. August 11-13, Buenos Aires (Argentina): invited faculty (speaker); The

FRIENDS collaborative study: Combine Carotid and Coronary Interventions. Main Lecture: Update on Drug Eluting Stents.

172. ESC Congress 2010. August 28 - September 1, Stockholm (Sweden): invited faculty (speaker);

Main Lecture: Presentation of the ESC Guidelines for Myocardial Revascularization.

173. “ Iperglicemia, QTc, Iperprolattinemia e disturbi del movimento: istruzioni per l’uso degli antipsicotici”. September 17, Verona (Italy): invited faculty (speaker);

174. Transcatheter Cardiovascular Therapeutics (TCT). September 21-25, Washington DC (U.S): invited faculty (speaker);

175. XI Athens Interventional Cardiovascular Therapeutics. October 8-9, Athens (Greece): invited faculty (speaker); Immunosuppression to avoid stent Restenosis: The CEREA-DES study.

176. “ La terapia con inibitori della glioproteina IIb/IIIa nelle sindromi coronariche acute. Dalle linee guida alla pratica clinica”. October 16, Verona (Italy): invited faculty (speaker);

177. “31˚ Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 19-22,


178. “4˚ Corso di Interventistica Vascolare”. November 5-6, Palermo (Italy): invited faculty

(speaker);

179. “Realizzazione, condivisione ed implementazione della scheda integrata di terapia presso la divisione clinicizzata di cardiologia dell’azienda ospedaliera di Verona”. February – December

2010, Verona (Italy);



181. Asian Medical Advisory Board of Abbott in Polymers and new drug eluting stents. Chairman.

Singapore, September 8-10 2010 .

2011

182 Joint interventional meeting (JIM). February 10-12, Rome (Italy): invited faculty (speaker);

183. VII Corso di specializzazione in emodinamica e cardiologia interventistica, March 1, Rozzano,

Milano (Italy): invited faculty (speaker): La rivascolarizzazione miocardica nel paziente con angina stabile.

184. “Incontro Regionale di Cardiologia Interventistica”. March 26, Nuoro (Italy): invited faculty

(speaker). Review on Drug Eluting Stent Thrombosis.

185. e-VACS 2011. April 14-15, Venice (Italy): invited faculty (speaker); Analysis of recent TAVI trials.

186. “Interventistica Interregionale GISE”. May 6, Padova (Italy): invited faculty (speaker);

187. EuroPCR. May 17-20, Paris (France): invited faculty (speaker), and member of the Scientific

Committee.

188. Cardiovascular Therapeutics India (CVT). August 20-21, New Delhi (India): invited faculty

(speaker); Drug-eluting balloons, rational, indications and results. Peripheral interventions for the

Cardiologists (speaker).

189. ESC Congress 2011. August 27-31, Paris (France): invited faculty (speaker);

190. “32˚ Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 11-14,


191. “Meeting di Cardiologia: Il rischio, la malattia, la terapia. October 21-22, Olbia (Italy): invited faculty (speaker);

192. “5˚ Corso di Interventistica Vascolare”. November 3-5, Palermo (Italy). “Il paziente con patologia carotidea e coronarica concomitante: quale approccio quale terapia”: invited faculty

(speaker);

193. Transcatheter Cardiovascular Therapeutics (TCT). November 7-11, San Francisco (U.S): invited faculty (speaker);

194. “XIII giornata di cardiologia Interventistica Miranese”. November 26, Venice (Italy): invited faculty (speaker);



2012:

196. “1 a

Reunão do grupo VAP/APIC”. January 20, Coimbra (Portugal): invited faculty (speaker);

197. High tech Marseille, January 25-27, Marseille (France): invited faculty (speaker);

198. Joint interventional meeting (JIM). February 9-11, Rome (Italy): invited faculty (moderator);

199. TAVI Expert Summit. February 28, Milan (Italy); Chairman

200. Medtronic CV International Technology Exchange Programme. March 8-10, Prague - Czech

Republic: invited faculty (speaker) and Course Co-Director.

201. V International course in prevention and treatment of complications in percutaneous interventional cardiology. April 19-20, Barcelona (Spain): invited faculty (speaker);

202. “Ineterventistica Interregionale GISE”. May 4, Bologna (Italy): invited faculty (speaker): La rivascolarizzazione del paziente, multivasale: chirurgia vs angioplastica.

203. “Congresso Regionale ANMCO Veneto”. May 12, Legnaro (Italy): invited faculty (speaker);

204. EuroPCR, May 15-18, Paris (France): invited faculty (speaker) and member of the Scientific

Committee.

205. TCT Russia: XIV Moscow’s International Course on Endovascular Therapies. May 28-30,

Moscow (Russia): invited faculty (speaker). Main Lecture: DES Restenosis. Live case operator.

206. 7 th

International Interventional Forum. June 7-8, Garda (Italy): invited faculty (speaker); The use of IVUS in interventional cardiology.

207. Meet the Masters. June 14-15, Villepinte (France): invited faculty (speaker); All you need to know to perform peripheral vascular interventions.

208. Medical Advisory Forum: Vascular Reparative Therapy. June 14, Brussels (Belgium): member;

209. “Simpósio Satélite Medtronic: Avanços e novas tecnologias na intervenção”. June 21,

Salvador (Brasil). Congresso della Socità Brasiliana di Cardiologia Invasiva. Invited faculty

(speaker);

210. PCR London Valves. September 30 – October 2, London (United Kingdom): invited faculty

(speaker);

211. “33˚ Congresso Nazionale della Società Italiana di Cardiologia Invasiva”, October 3-5,


212. “Seminari Endocrino Metabolici”. November 19, Verona (Italy): invited faculty (speaker): La

Rivascolarizzazione miocardica nel paziente diabetico.

213. THV Proctors meeting. November 23, Nyon (Switzerland); Moderator.

214. “32˚ Congrès national de cardiologie et de chirurgie cardiovasculaire”. November 28 –

December 1, Tunis (Tunisia): invited faculty (speaker). TAVI Update avec self auto-expandable proteses.

215. Medical Advisory Board: Bioresorbable Vascular Scaffolds. December 6, Brussels (Belgium): member.

216. “73˚ Congresso Nazionale della Società Italiana di Cardiologia”, December 15-17, Rome

(Italy): invited faculty (speaker): La Rivascolarizzazione Miocardica: Linee Guida a Confronto.

2013:

217. High Tech Marseille, February 1, Marseille (France): invited faculty. Ma meilleure astuce avec une CoreValve (speaker);

218. Joint interventional meeting (JIM), February 14-16, Rome (Italy); Symposium on physiologic coronary assessment and imaging. Chairman.

219. “Tre anni di TAVI: (Trans-Catheter Aortic valve Implantation)”. April 5, Verona (Italy): invited faculty (speaker); Tre anni di TAVI a Verona.

220. Abbott VRT Round Table. May 14 th 2013, Catania (Italy): invited faculty (speaker); BVS:

From stenting to vascular reparative therapy (VRT).

221. EuroPCR, May 21-24, Paris (France): invited faculty and member of the Scientific Committee.

(Speaker).

222. Congresso Nazionale della Società Italiana di Nefrologia. Firenze, 26 Settembre 2013. Il trattamento invasivo delle SCA nel paziente con insufficienza renale cronica. Invited speaker.

223. 40 anni di Cardiologia in Trentino. Settembre 28 2013: La stenosi aortica. Lettura Magistrale:

“La TAVI domani: cosa faremmo tra 5 anni e come”

224. “La valutazione fisiologica delle stenosi coronariche con FFR e o iFR: Introduzione all’approccio ibrido. Istituto Clinico Sant’Ambrogio-IRCS. October 1 st

, Milan (Italy): invited speaker: : il concetto di “instant wave-free” ratio.

225. ICCAD 2013: International Congress on Coronary Artery Disease. Florence, October 14 th

2013. Invited speaker: Interventional Cardiovascular Medicine. A New Speciality on the Horizon?

How to Set up an Interventional Medicine Practice.

226. “Casi Clinici delle Cardiologie del Veneto”. October18, San Bonifacio (Italy): invited faculty

(speaker); Il futuro della TAVI.

227. 50 Congresso della Società Italiana di Diabetologia. Riccione, 23 Ottobre 2013. Quali approcci per la rivascolarizzazione coronarica oggi. Invited speaker.

228. Transcatheter Cardiovascular Therapeutics (TCT), October 28 – November 1, San Francisco

(U.S): invited faculty (speaker); Best Challenging case award winning: Tricuspid valve in valve treatment.

229. Emergenze in Geriatria. Verona 20 Novembre 2013. Diagnostica invasiva e rivascolarizzazione delle Sindromi coronariche acute nell’anziano. Relatore

230. Veneto Cardiovascular Workshop. 3 Dicembre 2013, Mestre. Invited Speaker: La

Denervazione Renale in Veneto.

231. International BVS Forum. Catania 4-6 December 2013. Invited Speaker: The Basic of

Bioressorbable Scaffolding. And BVS in Cardiac Heart Transplantation.

232. International Advisory Board, Boston Scientific. New York December 12-14 2013. Faculty.

2014:

233. Medtronic – Innovation Expert Forum: “Interventional Pudendology, A New Sub-Specialty?”.

January 17, Cardiff (Wales): invited faculty (speaker);

234. THV training: “Edwards SAPIEN 3

TM

Valve Certification training Programme. January 20,

Milan (Italy).

235. Europe and Central Asia (ECA) Advisory Board Meeting. February 6-7, Madrid (Spain): invited faculty (speaker);

236. Medtronic -Prague Therapy and Technology Exchange Programme. February19-21, Prague -

Czech Republic: Course Co-director and invited faculty (speaker);

237. “Management in Chirurgia Vascolare: La presa in carico clinica e gestionale del paziente”.

March 6 – April 7, Verona (Italy): invited faculty (speaker); Il trattamento della coronaropatia nel malato con vasculopatia periferca.

238. Abbott Crossroads - Percutaneous Mitral valve Repair Programme. March 26-27, 2014.

Bruxelles.

239. “Aprroccio integrato anatomico-funzionale alla cardiopatia ischemica”. April 9, Venice

(Italy): invited faculty (speaker); Update on renal denervation.

240. Advances in Coronary Physiology. April 29, London (United Kingdom): Invited proffessor at the Imperial College of London. Lecture. FFR and IFR in my clinical practice.

241. Venice Interventional Cardiology: Focus on Heart and Brain. May 15-17, Venice (Italy): invited faculty (speaker): The acute coronary and neurologic syndrome. A new medical entity.


Committee. The 2014 Great Debate: Primary PCI in Acute myocardial infarction: An emergency!

Speaker.

243. “ Congresso de la Sociedad Espaniola de Cardiologia. XXV Curso de intervencionismo cardíaco percutáneo para residentes en cardiología”. June 11-13, Cordoba (Spain): invited faculty

(speaker): rational of the VRT in ACS.

244. “BVS: una nuova opzione terapeutica per il trattamento della Sindromi Coronariche Acute?”.

June 25, Padua (Italy): invited faculty (speaker);

245. PCR London Valves, London 28-30 September 2014. Invited Speaker: Roatablator and TAVI.

Emergency valve-in valve. Percutaneous treatment of dual volume overload. Speaker.

246. Seminario Cardiologico dell’Università di Foggia. BVS: una nuova opzione per il trattamento delle CAV. Foggia, 1 Ottobre 2014. Lettura Magistrale.

247. Congresso Nazionale della Società di Cardiologia Invasiva (GISE). Genova, 16-16 Ottobre

2014. Invited Speaker. Do we need cerebral protection for TAVI?

248. ESC Meeting on Acute Cardiovascular Care 2014. October 18-20, Geneva. Invited Speaker:

Safety of New Drug Eluting Stents.

249. GISE Toscana-Lombardia –Veneto. Interventistica Complessa Coronarica e Strutturale. Mestre

14-15 Novembre 2014. Faculty, Invited Speaker: Quale correlazione tra IVUS ed FFR?

250. Seminari Piastrine, trombosi ed emostasi, Verona 21 Novembre. Speaker: La prevenzione della trombosi coronarica nella cardiologia interventistica.

251. XVI Giornata Cardiologica Miranese. Main Lecture: La PCI nel paziente Multivasale. Mirano

22 Novembre 2014.

252. Functional Measurement of Coronary Lesions: State of the Art. Invited speaker: La FFR in

Veneto. Milano, Dicembre 3 2014.

253. Time in Brain, Verona 6 dicembre 2014. Chairman nella sessione Left atrial appendage closure.

254. Mediterranean Bioresorbable Scaffold Meeting. 19-20 Dicembre 2014, Agrigento. Invited speaker: Presupposti teorici ed evidenze della VRT.

2015

255. San Diego, Jannuary 23rd. SORIN Aortic Advisory Board on cardiac valves.

256. VI European and EMICS Technical Exchange Interventional Meeting. Rome 25-27 February

April 2015. Course Director and speaker.

257. Verona, 2 Aprile. Scuola Medica Ospedaliera XXV CORSO SUPERIORE DI GERIATRIA

La fragilità dell’anziano cardiopatico

258. First Latin America Technical Exchange Interventional Meeting Montevideo 8-10 April 2015.

Course Director and speaker.

259. Napoli 16-18 Aprile XVII Congresso Nazionale della SIEC. Controversie sulla TAVI:

La TAVI NON è una procedura soprautilizzata.

260. Nice ESC 23-24 April. The European Heart House. Coronary Physiology in the

Catheterization Laboratory 9th Edition. Resting measures Pd/Pa and iFR.

270. Rovereto 15 Maggio. I meeting neuro-cardiologico trentino. Risultati a medio e lungo termine nella chiusura percutanea del PFO.


Committee. Chairman of live Cases sessions and Director How-to-sessions for vascular access.

Speaker.

272. TCT Russia: XVI Moscow’s International Course on Endovascular Therapies. June 18-20,

Moscow (Russia): invited faculty (speaker). Main Lecture: Reflections from a pioneer of primary

PCI. Live case operator.

273. Invited Professor at Oxford University Cardiology Live 2015. Main Lecture on Stent

Thrombosis. September 14-15 th

2015.

274. Emergent International Course Symposium (EMICS) 2015. Course Co-director and speaker.

Istambul, September 23-25 2015.

275. Transcatheter Cardiovascular Therapeutics (TCT), October 10-14, 2015. San Francisco (U.S): invited faculty (speaker).

276. Congresso Nazionale della Società di Cardiologia Invasiva (GISE). Genova, 27-30 Ottobre

2015. Invited Speaker and chariman. Patients selection for TAVI

277. Course Director and live case cases performer at the Volcano course on FFR and iFR, Moscow

November 17 th 2015

278. XVII Giornata Cardiologica Miranese. Main Lecture: La fragilità del paziente anziano cardiochirurgico. Mirano 28 Novembre 2015.

279. Invited speaker on Coronary Bifurcations. National Congress of the Hellenic Society of

Cardiology, Athens, December 12-13 2015.

List of “full text” pubblications in peer reviewed scientific jurnals.

1.

Madoery C, Ribichini F, Galli B, Madoery R. Endocarditis infecciosa: Experiencia en el Hospital

Privado, revisiòn de la literatura. Experiencia Médica 1988; 6: 3-19

(F)

2.

Gastaldi L, Morello M, Casalucci D, Ribichini F, et al. European consensus on standards and guidelines for global and regional ventricular function from echocardiography: Parameters to assess myocardial contractility. Echocardiography, Chapter in book, Elsevier Publisher, 1990: 315-320 (F)

3.

Gastaldi L, Morello M, Casalucci D, Ribichini F, et al. Overview and choice of parameters to assess myocardial contractility. 7th International Congress on Echocardiography. Rome 1990, 113-114. (F)

4.

Madoery C, Farhy R, Ribichini F, et al. Tratamiento alternativo de la fibrilaciòn auricular paroxistica.

Revista Latina de Cardiologia 1991; 12: 264-67 (R)

5.

Feola M, Ribichini F, Macchia G et al. Cardiopatia ischemica silente nel diabete mellito: ruolo della neuropatia diabetica. Rassegna Geriatrica 1991; 27: 113-118 (R)

6.

Steffenino G, Bobbio M, Orzan F, Ribichini F et al. Recidiva dopo seconda angioplastica coronarica: quale scelta terapeutica?. in Librex Editori, Cardiologia 1991; Chapter in book Milano, p 337-342 (F)

7.

Dellavalle A, Steffenino G, Ribichini F et al. Ambulatory cardiac catheterization. G Ital Cardiol 1993;

23: 973-977 (R)

8.

Dellavalle A, Steffenino G, Ribichini F et al. Diagnostica cardiologica invasiva in regime ambulatoriale protetto. Cardiologia 1993;39:199-202 (R)

9.

Feola M, Ribichini F, Gallone G et al. Right-sided chest ECG leads in 195 normal subjects. G Ital

Cardiol 1994; 24: 375-379 (R)

10.

Dellavalle A, Ribichini F, Steffenino G. Unsuspected infrahepatic interruption of inferior vena cava associated with floppy mitral valve prolapse, and severe mitral regurgitation. Chest 1994; 106: 1226-

1228 (F)

11.

Steffenino G, Dellavalle A, Ribichini F et al. Quality assurance and cost containment in invasive and interventional cardiology. G Ital Cardiol 1994; 24: 1055-1067 (R)

12.

Russo P, Steffenino G, Dellavalle A, Ribichini F, Uslenghi E. Criteri clinici ed angiografici per la selezione dei pazienti per la PTCA con e senza stand-by cardiochirurgico. In New Trends in PTCA.

Chapter in book. Torino 1994; 21-28 (F)

13.

Dellavalle A, Steffenino G, Ribichini F et al. Elective coronary angioplasty with and without surgical standby: clinical and angiographic criteria for the selection of patients. Coronary Artery Disease 1995;

6: 513-520 (R)

14.

Dellavalle A, Steffenino G, Ribichini F, et al. Use of activated clotting time (ACT) for optimal heparin dosage during coronary angioplasty. G. Ital Cardiol 1995; 25: 445-451 (R)

15.

Russo P, Steffenino G, Dellavalle A, Ribichini F. Concomitant myocardial infarction in identical twins with similar coronary lesions. G Ital Cardiol 1995; 25: 341-343 (R)

16.

Steffenino G, Ribichini F, Dellavalle A, Rossetti V, Cerati R, Garbarino M, Russo P, Uslenghi E.

Radiological practice and radiation protection in italian cardiac catheterization laboratories. Cardiologia

1996; 41: 45-49 (R)

17.

Steffenino G, Dellavalle A, Ribichini F et al. Ambulation after 3 hours after elective cardiac catheterisation through the femoral artery. Br Heart J 1996; 75: 477-480 (F)

18.

Steffenino G, Dellavalle A, Ribichini F, Uslenghi E. Coronary stenting after unssuccesful emergency coronary angioplasty in acute myocardial infarction: Results in a series of consecutive patients. Am

Heart J 1996; 132:1115-1118 (R)

19.

Steffenino G, Rossetti V, Ribichini F, Dellavalle A, Garbarino M, Cerati R, Norbiato A, Uslenghi E.

Staff dose reduction during coronary angiography using low framing speed. Br J Radiol 1996; 69: 860-

864 (F)

20.

Bruna C, Rossetti G, Vado A, Steffenino G, Dellavalle A, Ribichini F, Racca E, Ferrero V, Uslenghi E.

Prediction of arrhythmic events in the first year after myocardial infarction treated with reperfusion therapy. VI Asia-Pacific symposium on cardiac pacing and electrophysiology. New Deli 25-28

October 1997 (R)

21.

Bruna C, Vado A, Rossetti G, Racca E, Steffenino G, Dellavalle A, Ribichini F, Ferrero V, Uslenghi E.

Effects of percutaneous transluminal coronary angioplasty in patients with evolving myocardial infarction on the signal-averaged electrocardiogram. G Ital Cardiol 1997; 27: 1144-1152 (R)

22.

Weaver D, Simes J, Betriu A, Grines C, Zijlstra F, Garcia E, Grinfeld L, Gibbons R, Ribeiro E,

DeWood M, Ribichini F. Primary coronary angioplasty vs. intravenous thrombolysis for treatment of acute myocardial infarction: A quantitative overview of their comparative effectiveness. JAMA 1997;

278: 2093-2098 (F)

23.

Ribichini F, Steffenino G, Dellavalle A, et al. On-line quantitative coronary analysis in clinical practice: one step closer to reality? Cathet Cardiovasc Diagn 1994; 31: 102-109 (R)

24.

Ribichini F, Steffenino G, Dellavalle A et al. Elective coronary angioplasty with no surgical back-up at all. G Ital Cardiol 1994; 24: 949-956 (R)

25.

Ribichini F, Steffenino G, Dellavalle A et al. Emergency coronary angioplasty in high-risk acute myocardial infarction. G Ital Cardiol 1995; 25: 707-714 (R)

26.

Ribichini F, Steffenino G, Dellavalle A, Uslenghi E. La angioplastia primaria como tratamiento de elecciòn en el infarto de miocardio de alto riesgo. Capitulo del libro: Avances en Medicina ‘95.

Sociedad Argentina de Medicina, Buenos Aires 1995; 289-297 (F)

27.

Ribichini F, Conte R, Lioi A Dellavalle A, Ugliengo G. Subacute tricuspid regurgitation with severe hypoxemia complicating blunt chest trauma. Chest 1996; 106: 289-291 (R)

28.

Ribichini F, Steffenino G, Dellavalle A, et al. Plasma Activity and Insertion/Deletion Plymorphism of

Angiotensin-Converting Enzyme: A Major Risk Factor and a Marker of Risk for Coronary Stent

Restenosis. Circulation 1998; 97:147-154 (R)

29.

Ribichini F, Steffenino G, Dellavalle A, et al. Primary angioplasty in acute inferior myocardial infarction with anterior ST-segment depression: follow-up results. G Ital Cardiol 1998; 28:781-787 (R)

30.

Ribichini F, Steffenino G, Dellavalle A, Rizzotti M. Use of Gianturco-Roubin stents for treating abrupt occlusion of unprotected left main stem during elective PTCA. G Ital Cardiol 1998; 28: 694-698 (R)

31.

Ribichini F, Steffenino G, Dellavalle A, et al. Plasma Lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98: 1172-1177 (R)

32.

Ribichini F, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M, Uslenghi E. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized trial. J Am Coll Cardiol 1998; 32:1687-1694 (R)

33.

Ribichini F, Steffenino G, Dellavalle A, Russo P, Uslenghi E. L’impiego dello stent può estendere l’indicazione ad angioplastica coronarica nell’infarto acuto dopo trombolisi? Controversie in

Cardiologia. 32° Convegno Internazionale di Cardiologia 1998, Milano 1998. Chapter in book, p 3-12

(F)

34.

Ribichini F. L’enzima di conversione dell’angiotensina I e restenosi dopo angioplastica coronarica.

Emodinamica 1999;15:16-21 (R)

35.

Ribichini F, Uslenghi E.Polimorfismi dell’ACE e malattia coronarica. In Ipertensione arteriosa e genetica. Editato dalla Societa Italiana dell’Ipertensione Arteriosa. Torino 1999, chapter in book, p 47-

54 (F)

36.

Ribichini F. Controversies in coronary stenting: Conditional stenting is the way to go. Editorial. G Ital

Cardiol 1999;29:495-504 (R)

37.

Ribichini F, Wijns W. Genetic predictors of in-stent restenosis. Remedica 1999; 2:8-15 (F)

38.

Ribichini F. Experiences with primary angioplasty without on-site cardiac surgery. Sem Intervent

Cardiol 1999;4:47-53 (R)

39.

Bruna C, Rossetti G, Vado A, Racca E, Steffenino G, Dellavalle A, Ribichini F, Ferrero V, Meinardi E,

Uslenghi E. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty. G Ital Cardiol 1998; 28:3-11 (R)

40.

Ferrero V, Steffenino G, Meinardi F, Conte E, Deorsola A, Vado A, Ribichini F, Dellavalle A,

Meinardi E, Uslenghi E. Early aggressive treatment of unstable angina without on-site cardiac surgical facilities: a prospective study of acute and long-term outcome. G Ital Cardiol 1998; 28:112-119 (R)

41.

Antonini-Canterin F, Faggiano P, Zanuttini D, Ribichini F. Is aortic valve resistance more clinically meaningful than valve area in aortic stenosis? Editorial. Heart 1999;1:9-10 (R)

42.

Conte L, Dutto S, Giachello G, Lice G, Tomatis M, Russo P, Dellavalle A, Ribichini F, Steffefnino G.

Cateterismo cardiaco per via arteriosa femorale con 4 French e mobilizzazione a 2 ore. G Ital Cardiol

1999;29:529-532 (R)

43.

Ribichini F, Pugno F, Ferrero V, Bussolati G, Di Mario C, Colombo A. Angiotensin-converting enzyme tissue activity in the diffuse in-stent restenotic plaque. Circulation 2000;101:e33-e35 (R)

44.

Ribichini F, Matullo G, Piazza A, Vado A, Uslenghi E. Relationship between plasma ACE activity and the proliferative healing process in coronary vessel injury after coronary stenting. Atherosclerosis

2000;152: 261-263 (R)

45.

Faggiano P, Antonini-Canterin F, Ribichini F, D’Aloia A, Ferrero V, Cervesato E, Pavan D, Burelli C,

Nicolosi G. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis.

Am J Cardiol 2000; 85:204-208 (F)

46.

Russo P, Steffenino G, Dellavalle A, Ribichini F, Ferrero V, Vado A, Uslenghi E. Angiographic follow-up after coronary implantation of the Multilink stent: a prospective observation. Ital Heart J

2000;1:117-121 (R)

47.

Stewart MW, Smith RS, Ribichini F, Fringuellino M. The role of auditory input in sudden infant death syndrome: A brief review and hypothesis. Prenat Neonat Med 2000;5:9-16 (F)

48.

Wijns W, Ribichini F. Editorial: CRP. Does it stand for coronary restenosis prediction? Eur Heart J

2000; 21:1121-1123 (R)

49.

Guidelines 2000 for Cardiopulmonary resuscitation and emergency cardiovascular care. International consensus on science. Contributor. Supplement to Circulation 2000; 102 (8) August 22, 2000 (F)

50.

Depres C, Ribichini F, Wijns W. Pathophysiological insights from studies on retrieved tissue. Sem

Intervent Cardiol 2000;5:175-184 (R)

51.

Aufderheide TP, Bossaer LL, Field J, Herlitz J, Leizorovicz A, Littrell KA, Ornato JP, Peberdy MA,

Ribichini F. Acute Coronary Syndromes. Ann Emerg Med 2001; 27:S163-S181 (e-R)

52.

Pugno F, Ribichini F. Osservazioni istopatologiche del materiale restenotico intrastent. Pathologica

2001;93:348 (F)

53.

Ribichini F, Pugno F. Lesioni coronariche e carotidee arteriosclerotiche. Pathologica 2001;93:349-350

(F)

54.

Ribichini F. In Stent Restenosis. Current Perspective. Ital Heart J 2001;2:728-735 (R)

55.

Ribichini F. Primary angioplasty to treat acute myocardial infarction. International Cardiology. Spring issue 2002 (F)

56.

Ribichini F. Pugno F, Di Mario C. Microscopic evidence of effective ablation of calcium and metal from coronary arteries treated with directional coronary atherectomy using the Flexicut device. Heart

2002; 87:283 (e-R)

57.

Ribichini F. Wijns W. Reperfusion treatment of acute myocardial infarction. Educational Article. Heart

2002; 88: 298-305 (e-R)

58.

Ribichini F, Ferrero V, Wijns W, Matullo G, Piazza A, Uslenghi E. Can ACE Inhibitors promote detrimental vascular effects after percutaneous injury? Hypertension 2002; 40: e5-6 (R)

59.

Ribichini F, Ferrero V, Vassanelli C. Logistics of primary angioplasty. Rather few centralized centers or better knowledge at local hospitals?. Heart Drug 2002; 2:321-325 (R)

60.

Rougin A, Ribichini F, Ferrero V, Heller H, Wijns W, Levy A. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol 2002; 89: 806-810 (e-R)

61.

Feola M, Biggi A, Ribichini F, Rovere E, Camuzzini GF, Uslenghi E. Usefulness of Tl

201dipyridamole myocardial scintigraphy to predict cardiac events in renal transplant recipients. J of

Nephrology 2002; 5: 48-53 (R)

62.

Takagi T, Di Mario C, Stankovic G, Reimers B, Alberti A, Liistro F, Kovalenko O, Sgura F, Albiero R,

Ribichini F, Pugno F, Colombo A. Effective plaque removal with a new 8 French-compatible atherectomy catheter. Catheter Cardiovasc Interv. 2002; 56: 452-9 (e-R)

63.

Feola M, Biggi A, Ribichini F, Camuzzini G, Uslenghi E. The diagnosis of coronary artery disease in hypertensive patients with chest pain and complete left bundle branch block: utility of adenosine

Tc99m tetrofosmin SPECT. Clin Nucl Med 2002; 27: 510-515 (R)

64.

Zijlstra F, Patel A, Jones M, Grines C, Ellis S, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, Ribichini

F, Granger C, Akhras F, Weaver D, Simes J for the PCAT collaboration. Clinical characteristics and outcome of patients with early (<2 hours), intermediate (2-4 hours) and late (>4 hours) presentation treated with primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur

Heart J 2002; 23:550-557 (e-R)

65.

Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, et al.

Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation

(IMPRESS-Study). J Am Coll Cardiol 2002; 40:1935-42 (e-R)

66.

Ribichini F, Wijns W, Ferrero V, Matullo G, Camilla T, Guarrera S, Vado A, Piazza A, Uslenghi E.

Effect of angiotensin-converting enzyme inhibition and restenosis after coronary stenting. Am J Cardiol

2003;91:154-158 (R)

67.

PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: Six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J 2003; 145: 47-57 (e-R)

68.

The Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003;107:1117-1122 (e-R)

69.

Feola M, Menardi E, Ribichini F, Vado A, Visconti G, Milanese U, Uslenghi E. Effest of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.

Med Sci Monit 2003;8:341-345 (R)

70.

Ferrero V, Ribichini F, Boccuzzi G, Vassanelli C. I sistemi di protezioni distale nell’angioplastica coronarica.

Emodinamica 2003;32:21-29. (e-R)

71.

Ferrero V, Ribichini F, Matullo G, Guarrera S, Carturan S, Vado A, Vassanelli C, Piazza A, Uslenghi

E, Wijns W. Estrogen receptor-α polymorphisms and angiographic outcome after coronary artery stenting. Arterioscler Thromb Vasc Biol 2003;23:2223-2228 (R)

2004

72.

Ribichini F. Ferrero V, Matullo, et al. Association study of the I/D polymorphism and plasma ACE as risk factors for stent restenosis. Clin Sci 2004; 107: 381-389 (R)

73.

Ribichini F, Ferrero V, Boccuzzi G, Carriero A, Vassanelli C. Marcatori genetici della restenosi postangioplastica. Emodinamica 2004;2:11-21 (R)

74.

Ribichini F, Ferrero V, Wijns W. Reperfusion treatment of ST elevation acute myocardial infarction.

Review. Prog Cardiovasc Disease 2004; 47: 131-157 (R)

75.

Feola M, Biggi A, Vado A, Ribichini F, Ferrero V, Leonardi G, Uslenghi E. Usefulness of adenosine

Tc-99m tetrofosmin SPECT for the diagnosis of left anterior descending coronary artery disease in patients with chest pain and left bundle branch block. Nucl Med Commun 2004; 25:265-269 (R)

76.

Feola M, Biggi A, Francini A, Leonardi G, Ribichini F, Ferrero V, Uslenghi E. Trimetazidine improves myocardial perfusion and left ventricular function in ischemic left ventricular dysfunction. Clin Nucl

Med 2004; 29: 117-118 (F)

77.

Bertona R, De Candia GF, Boccuzzi G, Ribichini F, Agostini M, Vassanelli C. Stenosi del corpo del graft di arteria mammaria interna sinistra. Aterosclerosi, spasmo o kinking? Ital Heart J 2004; 5: 53-58

(R)

78.

Feola M, Ribichini F, Ferrero V, et al. Comparison of Frequency of Insulin Resistance After Coronary

Stenting in Patients with Type 2 Diabetes Mellitus With-vs-Without Coronary Restenosis. Am J

Cardiol 2004; 94: 777-780 (R)

79.

Agostini M, Ribichini F, Portolan M, et al. Giant fistula connecting left coronary sinus with superior atriocaval junction. Ital Heart J 2004; 6: 483-5 (R) .

80.

Feola M, Biggi A, Francini A, Leonardi G, Ribichini F, Ferrero V, Uslenghi E. The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischemic ventricular dysfunction. Int J Cardiovasc Imaging 2004; 20: 315-320 (F)

81.

Ferrero V, Ribichini F, Heyndrickx G, De Bruyne B, Piessens M, Carlier S, et al. Angiographic and three-dimensional intravascular ultrasound analysis of combined intracoronary beta radiation and selfexpanding stent implantation in human coronary arteries. Am J Cardiol 2004; 94: 1237-1242 (e-R)

2005

82.

Ribichini F, Maffe S, Ferrero V, Cotroneo A, Vassanelli C. Percutaneous angioplasty of the subclavian artery angioplasty in patients with mammary-coronary by pass grafts. J Interven Cardiol 2005; 18: 39-

44 (e-R)

83.

Ribichini F, Ferrero V, Rognoni A, Vacca G, Vassanelli C. Angiotensin Antagonism in Coronary

Artery Disease: Results After Coronary Revascularization. Drugs 2005;65:1073-1096 (R)

84.

Ribichini F, Tomai F, Ferrero V, Versaci F, Boccuzzi G, Proietti I, Prati F, Crea F, Vassanelli C.

Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. Eurointervention 2005;2:173-180 (e-R)

85.

Ribichini F, Ferrero V, Heyndrickx GR, et al. Intracoronary Beta-Irradiation Prevents Excessive In-

Stent Neointimal Proliferation in De-Novo Lesions of Patients With High P lasma ACE Levels. The

BetAce Randomized Trial. Cardiovasc Revasc Med 2005;6:7-13 (R)

86.

Ribichini F, Ferrero V, Agostini M, Vassanelli C. Immunosuppression against restenosis. Efficacy of a radiofrequency guidewire and oral prednisone in achieving and mantaining coronary artery patency after stenting. Cardiovasc Revasc Med 2005;6:124-125 (e-R)

87.

Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M, Peyvandi F. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J

Thromb Haemost 2005; 3: 280-286 (e-R)

88.

Tomai F, Ribichini F, Ghini AS, Ferrero V, et al. Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur Heart J 2005;26:2099-2105 (e-

R)

89.

Airoldi F, Di Mario C, Ribichini F, Presbitero P, Sganzerla P, Ferrero V, Vassanelli C, Briguori C,

Carlino M, Montorfano, et al. 17-beta estradiol eluting stent versus PC-coated stent for the treatment of native coronary artery disease: clinical and angiographic results of the Italian EASTER trial. Am J

Cardiol 2005;96:664

2006

90.

Ribichini F, Pugno F, Ferrero V, Bussolati G, Feola M, Russo P, Di Mario C, Colombo A, Vassanelli

C. Cellular immunostaining of angiotensin-converting enzyme in human coronary atherosclerotic plaques. J Am Coll Cardiol 2006;47:1143-9 (e-R)

91.

Feola M, Bigi A, Francini A, Leonardi G, Vado A, Ribichini F, Uslenghi E. Placebo or trimetazidine

99mTC tetrofosmin myocardial SPECT and low-dose dobutamine echocardiography in hibernating myocardium. Arch Med Res 2006;37:117-122 (e-R)

92.

Grossini F, Molinari C, Battaglia A, Mary D.A.S.G, Ribichini F, Surico N, Vacca G. Human placental lactogen decreases regional blood flow in anesthetized pigs. J Vasc Res 2006;43:205-213 (e-R)

93.

Molinari C, Grossini F, Mary DA, Ribichini F, Surico N, Vacca G. The role of nitric oxide in the peripheral vasoconstriction caused by human placental lactogen in anaesthetized pigs. Exp Physiol.

2006 May;91(3):603-10. Epub 2006 Mar 2.

94.

Reversible inverse mismatch in transient left ventricular apical ballooning: perfusion/metabolism positron emission tomography imaging. Feola M, Rosso GL, Casasso F, Morena L, Biggi A, Chauvie

S, Ribichini F , Uslenghi E. J Nucl Cardiol. 2006 Jul;13(4):587-90.

2007

96. Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential.

Ferrero V, Ribichini F , Pesarini G, Brunelleschi S, Vassanelli C.

Drugs. 2007;67(9):1243-55. Review.

97. Successful surgical treatment of a giant coronary aneurysm communicating with the right atrium.

Rognoni A, Ferrero V, Teodori G, Ribichini F .

J Cardiovasc Med (Hagerstown). 2007 Dec;8(12):1061-4.

98. Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.

Ribichini F , Ferrero V, Feola M, Rognoni A, Brunelleschi S, Vacca G, Vassanelli C.

J Interv Cardiol. 2007 Jun;20(3):209-13.

99. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms.

Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F , Surico N, Vacca G.

Endocrinology. 2007 Aug;148(8):4080-90. Epub 2007 Apr 26.

100. Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study).

Ferrero V, Ribichini F , Rognoni A, Marino P, Brunelleschi S, Vassanelli C.

Am J Cardiol. 2007 Apr 15;99(8):1082-6. Epub 2007 Mar 6.

101. Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study.

Ribichini F , Ferrero V, Rognoni A, Marino P, Brunelleschi S, Vassanelli C.

J Interv Cardiol. 2007 Apr;20(2):114-21.

102. Intracoronary beta-irradiation for the treatment of de novo lesions: 5-year clinical follow-up of the

BetAce randomized trial.

Ferrero V, Ribichini F , Piessens M, Heyndrickx GR, Verbeke L, de Bruyne B, Feola M, Vassanelli C,

Wijns W.

Am Heart J. 2007 Mar;153(3):398-402.

103. Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent

Italian registry.

Ribichini F , Tomai F, Paloscia L, Di Sciascio G, Carosio G, Romano M, Verna E, Galli M, Tamburino C,

De Cesare N, Pirisi R, Piscione F, Lanteri G, Ferrero V, Vassanelli C; DESIRE investigators.

Heart. 2007 May;93(5):598-600. Epub 2006 Sep 27.

104. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.

Ribichini F , Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, Acampado E, Kolodgie FD,

Vassanelli C, Virmani R.

J Am Coll Cardiol. 2007 Jul 10;50(2):176-85. Epub 2007 Jun 22.

2008

105. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.

Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffrè G,

Prati F, Tamburino C, Ribichini F .

Diabetes Care. 2008 Jan;31(1):15-9. Epub 2007 Oct 1.

106. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts.

Ribichini F , Pugno F, Ferrero V, Wijns W, Vacca G, Vassanelli C, Virmani R.

Clin Sci (Lond). 2008 Feb;114(3):211-20.

107. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.

Chevalier B, Di Mario C, Neumann FJ, Ribichini F , Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE,

Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators.

JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010.

108. Drug-eluting stent safety: findings from preclinical studies.

Nakazawa G, Finn AV, Ladich E, Ribichini F , Coleman L, Kolodgie FD, Virmani R.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1379-91. doi: 10.1586/14779072.6.10.1379. Review.

109. Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: a myocardial PET study.

Feola M, Chauvie S, Rosso GL, Biggi A, Ribichini F , Bobbio M.

J Nucl Cardiol. 2008 Nov-Dec;15(6):811-7. doi: 10.1007/BF03007363. Epub 2008 Jul 31.

110. Percutaneous Impella Recover circulatory support in high-risk coronary angioplasty.

Arieti M, Pesarini G, Ribichini F .

Cardiovasc Revasc Med. 2008 Oct-Dec;9(4):269-74. doi: 10.1016/j.carrev.2008.04.004.

111. Cystatin C and contrast-induced nephropathy.

Gambaro G, Graziani MS, Ribichini F .

Nephrol Dial Transplant. 2008 Dec;23(12):4079; author reply 4079-80. doi: 10.1093/ndt/gfn507. Epub

2008 Sep 6. No abstract available.

112. Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion-metabolism positron emission tomography study.

Feola M, Biggi A, Chauvie S, Vado A, Leonardi G, Rolfo F, Ribichini F .

Nucl Med Commun. 2008 May;29(5):448-54. doi: 10.1097/MNM.0b013e3282f5d2bc.

113. A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages.

Amoruso A, Bardelli C, Gunella G, Ribichini F , Brunelleschi S.

Br J Pharmacol. 2008 May;154(1):144-52. doi: 10.1038/bjp.2008.50. Epub 2008 Feb 18.

2009

114. Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels.

Ferrero V, Tomai F, Versaci F, Feola M, Proietti I, Rognoni A, Ghini AS, Gaspardone A, Vacca G, De

Luca L, Vassanelli C, Ribichini F .

EuroIntervention. 2009 Jun;5(2):250-4.

115. Primary percutaneous coronary intervention: different outcome for different subgroups?

Savonitto S, Briguori C, Ribichini F , Tomai F, Piccaluga E.

J Cardiovasc Med (Hagerstown). 2009 Oct;10 Suppl 1:S27-34. doi:

116. Tobacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease.

Amoruso A, Gunella G, Rondano E, Bardelli C, Fresu LG, Ferrero V, Ribichini F , Vassanelli C,

Brunelleschi S.

Br J Pharmacol. 2009 Nov;158(5):1276-84. doi: 10.1111/j.1476-5381.2009.00442.x. Epub 2009

117. Enhanced peroxisome proliferator-activated receptor-gamma expression in monocyte/macrophages from coronary artery disease patients and possible gender differences.

Amoruso A, Bardelli C, Fresu LG, Palma A, Vidali M, Ferrero V, Ribichini F , Vassanelli C, Brunelleschi

S.

J Pharmacol Exp Ther. 2009 Nov;331(2):531-8. doi: 10.1124/jpet.109.154419. Epub 2009 Jul 30.

118. On the current epidemic outburst of meta-analytic rage in interventional cardiology.

Agostoni P, Ribichini F , Wijns W.

EuroIntervention. 2009 May;5(1):19-23. No abstract available.

119. Percutaneous transcatheter balloon valvuloplasty for severe tricuspid valve stenosis in Ebstein's anomaly.

Boccuzzi G, Gigli N, Cian D, Vullo C, Bonomini L, Ribichini F , Portella G, Strada G.

J Cardiovasc Med (Hagerstown). 2009 Jun;10(6):510-5.

120. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus

BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F , Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F,

De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

121. Recurrent very late drug-eluting stent thrombosis.

Pesarini G, Arieti M, Spadaro R, Vassanelli C, Ribichini F .

Cardiovasc Revasc Med. 2009 Apr-Jun;10(2):130-5. doi: 10.1016/j.carrev.2008.06.005.

122. Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE:

Dexamethasone-Eluting Stent Italian REgistry.

Pesarini G, Ferrero V, Tomai F, Paloscia L, De Cesare N, Tamburino C, Piscione F, Vassanelli F,

Ribichini F ; Dexamethasone-Eluting Stent Italian REgistry Investigators.

J Invasive Cardiol. 2009 Mar;21(3):86-91.

123. Urocortin II induces nitric oxide production through cAMP and Ca2+ related pathways in endothelial cells.

Grossini E, Molinari C, Mary DA, Uberti F, Ribichini F , Caimmi PP, Vacca G.

Cell Physiol Biochem. 2009;23(1-3):87-96. doi: 10.1159/000204097. Epub 2009 Feb 18.

124. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.

Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino

D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan

T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R,

Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C,

Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M,

Ribichini F , Rossi M, Bernardi F, Zonzin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J,

Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB,

Williams G, Nathan DM, MacRae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O,

Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Musunuru K, Daly

MJ, Purcell S, Voight BF, Purcell S, Nemesh J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan

S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burtt N, Gabriel

SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall A; Wellcome Trust

Case Control Consortium, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, König I,

Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H,

Samani NJ, Erdmann J, Ouwehand W, Hengstenberg C, Deloukas P, Scholz M, Cambien F, Reilly MP, Li

M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent

KM, Satler L, Lindsay JM, Waksman R, Knouff CW, Waterworth DM, Walker MC, Mooser V, Epstein

SE, Rader DJ, Scheffold T, Berger K, Stoll M, Huge A, Girelli D, Martinelli N, Olivieri O, Corrocher R,

Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W,

Ziegler A, König IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE,

Schreiber S, Hólm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Engert JC, Do R, Xie C, Anand S,

Kathiresan S, Ardissino D, Mannucci PM, Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R,

Peltonen L, Salomaa V, Schwartz SM, Altshuler D.

Nat Genet. 2009 Mar;41(3):334-41. doi: 10.1038/ng.327. Epub 2009 Feb 8. Erratum in: Nat Genet. 2009

Jun;41(6):762. Knouff, Christopher W [added]; Waterworth, Dawn M [added]; Walker, Max C [added];

Mooser, Vincent [added].

125. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries. van Beusekom HM, Ferrero V, Ribichini F , van der Giessen WJ.

Atherosclerosis. 2009 Jul;205(1):120-5. doi: 10.1016/j.atherosclerosis.2008.11.029. Epub 2008 Dec

2010

126.

Clinical outcome after endovascular, surgical or hybrid revascularisation in patients with combined carotid and coronary artery disease: the Finalised Research In ENDovascular Strategies Study Group

(FRIENDS).

Ribichini F , Tomai F, Reimers B, Russo P, Borioni R, Spartà D, Pacchioni A, Pesarini G, Spagnolo B, De

Persio G, Cremonesi A, Castriota F.

EuroIntervention. 2010 Aug;6(3):328-35. doi: 10.4244/EIJV6I3A55.

127. Guidelines on myocardial revascularization.

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the

European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous

Cardiovascular Interventions (EAPCI), Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T,

Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet

C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart

D.

Eur J Cardiothorac Surg. 2010 Sep;38 Suppl:S1-S52. doi: 10.1016/j.ejcts.2010.08.019. No abstract available.

128. Guidelines on myocardial revascularization.

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the

European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous

Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T,

Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet

C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart

D.

Eur Heart J. 2010 Oct;31(20):2501-55. doi: 10.1093/eurheartj/ehq277. Epub 2010 Aug 29. No abstract available.

129. Early creatinine shifts predict contrast-induced nephropathy and persistent renal damage after angiography.

Ribichini F , Graziani M, Gambaro G, Pasoli P, Pighi M, Pesarini G, Abaterusso C, Yabarek T,

Brunelleschi S, Rizzotti P, Lupo A, Vassanelli C.

Am J Med. 2010 Aug;123(8):755-63. doi: 10.1016/j.amjmed.2010.02.026.

130. The gap between vascular interventions and vascular medicine.

Ribichini F , Tomai F, Castriota F, Russo P, Reimers B.

EuroIntervention. 2010 May;6(1):25-7. doi: 10.4244/. No abstract available.

131. Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans.

Pesarini G, Amoruso A, Ferrero V, Bardelli C, Fresu LG, Perobelli L, Scappini P, De Luca G, Brunelleschi

S, Vassanelli C, Ribichini F .

Atherosclerosis. 2010 Jul;211(1):242-8. doi: 10.1016/j.atherosclerosis.2010.02.004. Epub 2010 Feb

132. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the

EXECUTIVE trial.

Ribichini F , Ansalone G, Bartorelli A, Beqaraj F, Berni A, Colangelo S, D'Amico M, Della Rovere F,

Fiscella A, Gabrielli G, Indolfi C, La Vecchia L, Loschiavo P, Marinoni G, Marzocchi A, Milazzo D,

Romano M, Sangiorgio P, Sheiban I, Tamburino C, Tuccillo B, Villani R, Cappi B, Quijada MJ, Vassanelli

C; EXECUTIVE Trial Investigators.

J Cardiovasc Med (Hagerstown). 2010 Apr;11(4):299-309. doi: 10.2459/JCM.0b013e3283331e69.

133. Rationale and design of the Randomized comparison of XiEnce V and Multilink VisioN coronary stents in the sAme muLtivessel patient with chronic kiDnEy disease (RENAL-DES) study.

Tomai F, Petrolini A, De Luca L, Nudi F, Lanza G, Vassanelli C, Ribichini F .

J Cardiovasc Med (Hagerstown). 2010 Apr;11(4):310-7. doi: 10.2459/JCM.0b013e3283347e24.

2011

134.

Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction.

Ardissino D, Berzuini C, Merlini PA, Mannuccio Mannucci P, Surti A, Burtt N, Voight B, Tubaro M,

Peyvandi F, Spreafico M, Celli P, Lina D, Notarangelo MF, Ferrario M, Fetiveau R, Casari G, Galli M,

Ribichini F , Rossi ML, Bernardi F, Marziliano N, Zonzin P, Mauri F, Piazza A, Foco L, Bernardinelli L,

Altshuler D, Kathiresan S; Italian Atherosclerosis, Thrombosis and Vascular Biology Investigators.

J Am Coll Cardiol. 2011 Jul 19;58(4):426-34. doi: 10.1016/j.jacc.2010.11.075.

135. Early and long-term outcomes after combined percutaneous revascularization in patients with carotid and coronary artery stenoses.

Tomai F, Pesarini G, Castriota F, Reimers B, De Luca L, De Persio G, Spartà D, Aurigemma C, Pacchioni

A, Spagnolo B, Cremonesi A, Ribichini F ; Finalized Research in Endovascular Strategies Study Group.

JACC Cardiovasc Interv. 2011 May;4(5):560-8. doi: 10.1016/j.jcin.2011.01.012.

136. Implications of new ESC/EACTS guidelines on myocardial revascularization for patients with multivessel coronary artery disease.

Ribichini F , Taggart D.

Interact Cardiovasc Thorac Surg. 2011 May;12(5):663-6. doi: 10.1510/icvts.2010.261024. No abstract available.

137. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial.

Ribichini F , Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Abukaresh

R, Aurigemma C, De Luca L, Zavalloni D, Soregaroli D, Marino P, Garbo R, Zanolla L, Vassanelli C;

CEREA-DES investigators.

Am J Med. 2011 May;124(5):434-43. doi: 10.1016/j.amjmed.2010.11.027.

138. Veno-venous extracorporeal membrane oxygenation as a bridge to and support for pulmonary thromboendarterectomy in misdiagnosed chronic thromboembolic pulmonary hypertension.

Faggian G, Onorati F, Chiominto B, Gottin L, Dan M, Ribichini F , Menon T, Santini F, Mazzucco A.

Artif Organs. 2011 Oct;35(10):956-60. doi: 10.1111/j.1525-1594.2010.01182.x. Epub 2011 Apr 14.

139. Implications of new ESC/EACTS guidelines on myocardial revascularisation for patients with multivessel coronary artery disease.

Ribichini F , Taggart D.

Eur J Cardiothorac Surg. 2011 May;39(5):619-22. doi: 10.1016/j.ejcts.2011.02.029. No abstract available.

140. Letter by Ribichini et al regarding article, "Cystatin C and contrast-induced acute kidney injury".

Ribichini F , Pesarini G, Gambaro G.

Circulation. 2011 Feb 8;123(5):e225; author reply e226.

doi: 10.1161/CIRCULATIONAHA.110.975672. No abstract available.

141. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the

STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-

Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single

High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute

Myocardial Infarction Study) trials.

Valgimigli M, Campo G, Malagutti P, Anselmi M, Bolognese L, Ribichini F , Boccuzzi G, de Cesare N,

Rodriguez AE, Russo F, Moreno R, Biondi-Zoccai G, Penzo C, Díaz Fernández JF, Parrinello G, Ferrari R.

JACC Cardiovasc Interv. 2011 Jan;4(1):51-62. doi: 10.1016/j.jcin.2010.09.016.

142. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies.

Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW,

Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS;

Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Martinelli N,

Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S,

Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ.

Lancet. 2011 Jan 29;377(9763):383-92. doi: 10.1016/S0140-6736(10)61996-4. Epub 2011 Jan 14.

2012

143.

Hypothesis-based analysis of gene-gene interactions and risk of myocardial infarction.

Lucas G, Lluís-Ganella C, Subirana I, Musameh MD, Gonzalez JR, Nelson CP, Sentí M; Myocardial

Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Schwartz SM, Siscovick D,

O'Donnell CJ, Melander O, Salomaa V, Purcell S, Altshuler D, Samani NJ, Kathiresan S, Elosua R.

PLoS One. 2012;7(8):e41730. Epub 2012 Aug 2.

144. Is transfemoral aortic valve implantation possible without contrast medium in patients with renal and multiorgan failure?

Dandale R, Pesarini G, Santini F, Rossi A, Milano A, Faggian G, Ribichini F .

Future Cardiol. 2012 Jul;8(4):543-6. doi: 10.2217/fca.12.29.

145. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.

Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Bacchi Reggiani L,

Kaiser C, Kim HS, De Waha A, Ribichini F , Stone GW.

Circ Cardiovasc Interv. 2012 Jun;5(3):357-64. doi: 10.1161/CIRCINTERVENTIONS.111.967083.

146. Transfemoral Edwards-Novaflex valve implantation in a patient with aorto-iliac endoprosthesis and severely tortuous bilateral external iliac arteries-"Railing track".

Dandale RM, Pesarini G, Santini F, Molinari G, Rossi A, Milano A, Faggian G, Vassanelli C, Ribichini F .

Cardiovasc Revasc Med. 2012 May-Jun;13(3):203.e5-8. doi: 10.1016/j.carrev.2012.02.004. Epub 2012 Apr

18.

147. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis.

Stahl EA, Wegmann D, Trynka G, Gutierrez-Achury J, Do R, Voight BF, Kraft P, Chen R, Kallberg HJ,

Kurreeman FA; Diabetes Genetics Replication and Meta-analysis Consortium; Myocardial Infarction

Genetics Consortium, Kathiresan S, Wijmenga C, Gregersen PK, Alfredsson L, Siminovitch KA,

Worthington J, de Bakker PI, Raychaudhuri S, Plenge RM.

Nat Genet. 2012 Mar 25;44(5):483-9. doi: 10.1038/ng.2232.

148. [Diagnosis of acute renal injury by serum creatinine: negative perception vs evidence].

Gambaro G, Graziani MS, Ribichini F .

G Ital Nefrol. 2012 Jan-Feb;29(1):4-6. Italian. No abstract available.

149. Regarding 'Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery'.

Gambaro G, Graziana MS, Ribichini F .

Kidney Int. 2012 Mar;81(6):598; author reply 598-9. doi: 10.1038/ki.2011.429. No abstract available.

150. A model of multi-disciplinary approach to the diagnosis and treatment of young patients with cryptogenic stroke and patent foramen ovale.

Mazzucco S, Bovi P, Carletti M, Tomelleri G, Golia G, Stegagno C, Variola A, Anselmi M, Nicolis D,

Olivato S, Anzola GP, Ribichini F ; VEROSTROKE Study Group.

Cardiol Young. 2012 Jun;22(3):327-34. doi: 10.1017/S1047951112000029. Epub 2012 Feb 21.

151. Management of combined severe carotid and coronary artery disease.

Roffi M, Ribichini F , Castriota F, Cremonesi A.

Curr Cardiol Rep. 2012 Apr;14(2):125-34. doi: 10.1007/s11886-012-0246-1. Review.

152. First successful management of aortic valve insufficiency associated with HeartMate II left ventricular assist device support by transfemoral CoreValve implantation: the Columbus's egg?

Santini F, Forni A, Dandale R, Ribichini F , Rossi A, Franchi G, Onorati F, Vassanelli C, Mazzucco A,

Faggian G.

JACC Cardiovasc Interv. 2012 Jan;5(1):114-5. doi: 10.1016/j.jcin.2011.10.009. No abstract available.

153. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions.

Ribichini F , Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, Anselmi M, Ferrero V, Yabarek T,

Sorio A, Rizzotti P, Lupo A, Vassanelli C.

Clin Chem. 2012 Feb;58(2):458-64. doi: 10.1373/clinchem.2011.170464. Epub 2011 Dec 13.

154. Risk stratification in acute coronary syndromes.

Pesarini G, Santini F, Geremia G, Zivelonghi C, Ribichini F .

J Cardiovasc Transl Res. 2012 Feb;5(1):1-10. doi: 10.1007/s12265-011-9337-4. Epub 2011 Dec 2.

2013

155.

Invasive assessment of renal artery atherosclerotic disease and resistant hypertension before renal sympathetic denervation.

Ribichini F , Pighi M, Zivelonghi C, Gambaro A, Valvo E, Lupo A, Vassanelli C.

J Nephrol. 2013 Jul-Aug;26(4):799-801. doi: 10.5301/jn.5000295. Epub 2013 Jun 28.

156. Numbers needed to treat (lives!) and numbers needed to save (money).

Ribichini F , Taggart D, Vassanelli C.

EuroIntervention. 2013 Jun 22;9(2):175-7. doi: 10.4244/EIJV9I2A28. No abstract available.

157. Late and very late coronary stent thrombosis: Intravascular ultrasound findings and associations with antiplatelet therapy.

Pesarini G, Dandale R, Rigamonti A, Pighi M, Zivelonghi C, Mugnolo A, Ferrero V, Vassanelli C,

Ribichini F .

Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1056-65. doi: 10.1002/ccd.24938. Epub 2013 Jun 10.

158. Effects of prednisone on biomarkers of tubular damage induced by radiocontrast in interventional cardiology.

Ribichini F , Gambaro A, Pighi M, Pesarini G, Ferraro PM, Zuppi C, Baroni S, Penitente R, Ferrero V,

Vassanelli C.

J Nephrol. 2013 May-Jun;26(3):586-93. doi: 10.5301/jn.5000266. Epub 2013 Mar 29.

159. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES).

Ribichini F , Tomai F, Pesarini G, Zivelonghi C, Rognoni A, De Luca G, Boccuzzi G, Presbitero P, Ferrero

V, Ghini AS, Marino P, Vassanelli C; CEREA-DES Investigators.

Eur Heart J. 2013 Jun;34(23):1740-8. doi: 10.1093/eurheartj/eht079. Epub 2013 Mar 14.

160. Prevalence of patients with severely reduced aortic valve area and low gradient despite a preserved ejection fraction. Results from a cath-lab data base.

Benfari G, Rossi A, Dandale R, Toniolo M, Cristofoletti A, Ribichini F , Vassanelli C.

Int J Cardiol. 2013 Sep 10;167(6):3034-6. doi: 10.1016/j.ijcard.2012.11.098. Epub 2012 Dec 2. No abstract available.

161. Bioresorbable vascular scaffolds in cardiac allograft vasculopathy: a new therapeutic option.

Ribichini F , Pighi M, Faggian G, Vassanelli C.

Am J Med. 2013 Nov;126(11):e11-4. doi: 10.1016/j.amjmed.2013.05.025. No abstract available.

162. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).

Ribichini F , Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, Milazzo D, Loschiavo P,

Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni

D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera

Quijada MJ, Cappi B, Ribaldi L, Vassanelli C; EXECUTIVE Trial Investigators.

JACC Cardiovasc Interv. 2013 Oct;6(10):1012-22. doi: 10.1016/j.jcin.2013.05.016. Epub 2013 Sep

163. Combined endovascular treatment for acute multi-district atherosclerotic disease.

Reimers B, Tomai F, Castriota F, Ribichini F ; FRIENDS (Finalized Research In EnDovascular Strategies)

Study Group.

J Endovasc Ther. 2013 Aug;20(4):552-3. doi: 10.1583/13-4244C.1. No abstract available.

164. Transcatheter tricuspid valve implantation by femoral approach in trivalvular heart disease.

Ribichini F , Pesarini G, Feola M, Agostini M, Molinari G, Rossi A, Faggian G, Vassanelli C.

Am J Cardiol. 2013 Oct 1;112(7):1051-3. doi: 10.1016/j.amjcard.2013.05.043. Epub 2013 Aug 1.

165. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus

Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY

(MULTISTRATEGY).

Valgimigli M, Campo G, Gambetti S, Bolognese L, Ribichini F , Colangelo S, de Cesare N, Rodriguez AE,

Russo F, Moreno R, Piva T, Sheiban I, Penzo C, Prati F, Nazzaro MS, Díaz Fernández JF, Vassanelli C,

Parrinello G, Ferrari R; MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or Bare Metal Stent in Acute Myocardial Infarction studY Investigators.

Int J Cardiol. 2013 Apr 30;165(1):134-41. doi: 10.1016/j.ijcard.2011.07.106. Epub 2011 Aug 24.

2014

166. The need for this supplement: beyond "exercises in style".

Ribichini F , Cuisset T.

EuroIntervention. 2014 Aug;10 Suppl T:T7-8. doi: 10.4244/EIJV10STA1. No abstract available.

167. Percutaneous coronary interventions during ST-segment elevation myocardial infarction: current status and future perspectives.

Diletti R, Yetgin T, Manintveld OC, Ligthart JM, Zivelonghi C, Zijlstra F, Ribichini F .

EuroIntervention. 2014 Aug;10 Suppl T:T13-22. doi: 10.4244/EIJV10STA4.

168. Virtual histology findings in rapid cardiac allograft vasculopathy progression and bioresorbable vascular scaffolds.

Ribichini F , Pighi M, Zivelonghi C, Faggian G, Vassanelli C.

Int J Cardiol. 2014 Sep;176(1):257-9. doi: 10.1016/j.ijcard.2014.06.056. Epub 2014 Jul 15. No abstract available.

169. Prognosis and disease progression in patients under 50 years old undergoing PCI: the CRAGS

(Coronary aRtery diseAse in younG adultS) study.

Lautamäki A, Airaksinen KE, Kiviniemi T, Vinco G, Ribichini F , Gunn J, Anttila V, Heikkinen J,

Korpilahti K, Karjalainen P, Kajander O, Eskola M, Ilveskoski E, Axelsson T, Gudbjartsson T, Jeppsson

A, Biancari F.

Atherosclerosis. 2014 Aug;235(2):483-7. doi: 10.1016/j.atherosclerosis.2014.05.953. Epub 2014

170. Intracoronary optical coherence tomography: a review of clinical applications.

Zivelonghi C, Ghione M, Kilickesmez K, Loureiro RE, Foin N, Lindsay A, de Silva R, Ribichini F ,

Vassanelli C, Di Mario C.

J Cardiovasc Med (Hagerstown). 2014 Jul;15(7):543-53. doi: 10.2459/JCM

171. Comparison of 30-day and 5-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients aged≤50 years (the Coronary aRtery diseAse in younG adultS Study).

Biancari F, Gudbjartsson T, Heikkinen J, Anttila V, Mäkikallio T, Jeppsson A, Thimour-Bergström L,

Mignosa C, Rubino AS, Kuttila K, Gunn J, Wistbacka JO, Teittinen K, Korpilahti K, Onorati F, Faggian G,

Vinco G, Vassanelli C, Ribichini F , Juvonen T, Axelsson TA, Sigurdsson AF, Karjalainen PP, Mennander

A, Kajander O, Eskola M, Ilveskoski E, D'Oria V, De Feo M, Kiviniemi T, Airaksinen KE.

Am J Cardiol. 2014 Jul 15;114(2):198-205. doi: 10.1016/j.amjcard.2014.04.025. Epub 2014 May 2.

172. Coronary vasomotion one year after drug-eluting stent implantation: comparison of everolimuseluting and paclitaxel-eluting coronary stents.

Hamilos M, Ribichini F , Ostojic MC, Ferrero V, Orlic D, Vassanelli C, Karanovic N, Sarno G, Cuisset T,

Vardas PE, Wijns W.

J Cardiovasc Transl Res. 2014 Jun;7(4):406-12. doi: 10.1007/s12265-014-9568-2. Epub 2014 May

173. Asymptomatic severe aortic coarctation at old age.

Zivelonghi C, Pighi M, Perandini S, Vassanelli C, Ribichini F .

Int J Cardiol. 2014 May 15;173(3):e56-7. doi: 10.1016/j.ijcard.2014.03.096. Epub 2014 Mar 20.

174. Revascularization strategies in patients with combined carotid and coronary artery disease.

Tomai F, Castriota F, Reimers B, Borioni R, Ribichini F ; FRIENDS Study Group.

J Am Coll Cardiol. 2014 Jun 24;63(24):2745-6. doi: 10.1016/j.jacc.2013.10.098. Epub 2014 Mar 26. No abstract available.

175. Drug-eluting stent or coronary artery bypass graft surgery in hemodialysis patients?

Ribichini F , Vassanelli C.

J Nephrol. 2014 Feb;27(1):7-9. doi: 10.1007/s40620-013-0010-7. Epub 2013 Dec 13. No abstract available.

176. Single-side renal sympathetic denervation to treat malignant refractory hypertension in a solitary kidney patient.

Ribichini F , Ferrara A, Pighi M, Pesarini G, Gambaro A, Valvo E, Lupo A, Vassanelli C.

J Nephrol. 2014 Feb 11. [Epub ahead of print]

177. Bail-out transcatheter aortic valve implantation to reduce severe acute aortic regurgitation in a failing homograft secondary to HeartMate II ventricular assistance device.

Ribichini F , Faggian G, Pesarini G, Milano A, Gottin L, Vassanelli C.

Cardiovasc Revasc Med. 2014 Jul-Aug;15(5):295-7. doi: 10.1016/j.carrev.2013.12.002. Epub 2013

178. "Valve in valve" implantation of two self-expandable transcatheter aortic valves in a patient with aortic root aneurysm and massive aortic regurgitation: "a new TAVI option".

Pesarini G, Bedogni F, Ribichini F .

Catheter Cardiovasc Interv. 2014 Apr 1;83(5):836-40. doi: 10.1002/ccd.25194. Epub 2013 Oct 23.

179. Tomai F, Ribichini F , De Luca L, Petrolini A, Ghini AS, Weltert L, Spaccarotella C, Proietti I, Trani

C, Nudi F, Pighi M, Vassanelli C.

Circulation. 2014 Mar 11;129(10):1104-12. doi: 10.1161/CIRCULATIONAHA.113.005186. Epub 2013

Dec 19.

180. Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: Results of the multicenter Italian OBSERVANT Registry.

Onorati F, D'Errigo P, Barbanti M, Rosato S, Covello RD, Maraschini A, Ranucci M, Santoro G,

Tamburino C, Grossi C, Santini F, Menicanti L, Seccareccia F; OBSERVANT Research Group.

J Thorac Cardiovasc Surg. 2014 May;147(5):1529-39. doi: 10.1016/j.jtcvs.2013.05.039. Epub 2013 Jul 13.

181. Capranzano P, Testa L, Tamburino C, Capodanno D, Biondi-Zoccai G, Longo G, Tomai F, Ribichini

F , Indolfi C, Bartorelli AL, Petronio AS, Bedogni F, La Manna A, Francaviglia B, De Carlo M, Tamburino

C. G Ital Cardiol (Rome). 2014 Sep;15(9):475-81. doi: 10.1714/1640.17972. Italian.

182. Is TAVI superior to surgery in high-risk patients? Insight into the concept of individual risk assessment. Benfari G, Onorati F, Rossi A, Abbasciano R, Zivelonghi C, Salsano A, Ribichini F , Santini

F, Vassanelli F, Mazzucco A, Faggian G. Minerva Med. 2014 Nov 2. [Epub ahead of print]

183. ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patientlevel meta-analysis of randomized trials.

Salvatore Cassese, MD, Giuseppe De Luca, MD, Flavio Ribichini , MD, Carmelo Cernigliaro, MD, Mara

Sansa, MD, Francesco Versaci, MD, Igino Proietti, MD, Goran Stankovic, MD, Sinisa Stojkovic, MD,

Carlos Fernandez-Pereira, MD, Fabrizio Tomai, MD, Corrado Vassanelli, MD, David Antoniucci, MD,

Patrick W. Serruys, MD, Adnan Kastrati, MD and Alfredo E. Rodriguez, MD

Atherosclerosis 2014;237:410-417

184. Real-time use of instantaneous wave-free ratio: Results of the ADVISE in-practice: An international, multicenter evaluation of instantaneous wave-free ratio in clinical practice.

Petraco R, Al-Lamee R, Gotberg M, Sharp A, Hellig F, Nijjer SS, Echavarria-Pinto M, van de Hoef TP,

Sen S, Tanaka N, Van Belle E, Bojara W, Sakoda K, Mates M, Indolfi C, De Rosa S, Vrints CJ, Haine S,

Yokoi H, Ribichini FL , Meuwissen M, Matsuo H, Janssens L, Katsumi U, Di Mario C, Escaned J, Piek J,

Davies JE.

Am Heart J. 2014 Nov;168(5):739-48. doi: 10.1016/j.ahj.2014.06.022. Epub 2014 Jul 21.

185. Expanding TAVI options: elective rotational atherectomy during trans-catheter aortic valve implantation.

Piccoli A, Lunardi M, Ariotti S, Ferrero V, Vassanelli C, Ribichini F .

Cardiovasc Revasc Med. 2014 Nov 20. pii: S1553-8389(14)00252-8. doi: 10.1016/j.carrev.2014.11.003.

Review.

186. Defining the role of common variation in the genomic and biological architecture of adult human height.

Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan J,

Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR, Duan Y, Fall T, Fehrmann R,

Ferreira T, Jackson AU, Karjalainen J, Lo KS, Locke AE, Mägi R, Mihailov E, Porcu E, Randall

JC, Scherag A, Vinkhuyzen AA, Westra HJ, Winkler TW, Workalemahu T, Zhao JH, Absher D,

Albrecht E, Anderson D, Baron J, Beekman M, Demirkan A, Ehret GB, Feenstra B, Feitosa MF,

Fischer K, Fraser RM, Goel A, Gong J, Justice AE, Kanoni S, Kleber ME, Kristiansson K, Lim U,

Lotay V, Lui JC, Mangino M, Mateo Leach I, Medina-Gomez C, Nalls MA, Nyholt DR, Palmer

CD, Pasko D, Pechlivanis S, Prokopenko I, Ried JS, Ripke S, Shungin D, Stancáková A,

Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van

Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Afzal U, Arnlöv J, Arscott GM, Bandinelli S,

Barrett A, Bellis C, Bennett AJ, Berne C, Blüher M, Bolton JL, Böttcher Y, Boyd HA, Bruinenberg

M, Buckley BM, Buyske S, Caspersen IH, Chines PS, Clarke R, Claudi-Boehm S, Cooper M, Daw

EW, De Jong PA, Deelen J, Delgado G, Denny JC, Dhonukshe-Rutten R, Dimitriou M, Doney AS,

Dörr M, Eklund N, Eury E, Folkersen L, Garcia ME, Geller F, Giedraitis V, Go AS, Grallert H,

Grammer TB, Gräßler J, Grönberg H, de Groot LC, Groves CJ, Haessler J, Hall P, Haller T,

Hallmans G, Hannemann A, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q,

Hemani G, Henders AK, Hillege HL, Hlatky MA, Hoffmann W, Hoffmann P, Holmen O,

Houwing-Duistermaat JJ, Illig T, Isaacs A, James AL, Jeff J, Johansen B, Johansson Å, Jolley J,

Juliusdottir T, Junttila J, Kho AN, Kinnunen L, Klopp N, Kocher T, Kratzer W, Lichtner P, Lind L,

Lindström J, Lobbens S, Lorentzon M, Lu Y, Lyssenko V, Magnusson PK, Mahajan A, Maillard M,

McArdle WL, McKenzie CA, McLachlan S, McLaren PJ, Menni C, Merger S, Milani L, Moayyeri

A, Monda KL, Morken MA, Müller G, Müller-Nurasyid M, Musk AW, Narisu N, Nauck M, Nolte

IM, Nöthen MM, Oozageer L, Pilz S, Rayner NW, Renstrom F, Robertson NR, Rose LM, Roussel

R, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Schunkert H, Scott RA, Sehmi J,

Seufferlein T, Shi J, Silventoinen K, Smit JH, Smith AV, Smolonska J, Stanton AV, Stirrups K,

Stott DJ, Stringham HM, Sundström J, Swertz MA, Syvänen AC, Tayo BO, Thorleifsson G, Tyrer

JP, van Dijk S, van Schoor NM, van der Velde N, van Heemst D, van Oort FV, Vermeulen SH,

Verweij N, Vonk JM, Waite LL, Waldenberger M, Wennauer R, Wilkens LR, Willenborg C,

Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, Arveiler D, Bakker SJ, Beilby J,

Bergman RN, Bergmann S, Biffar R, Blangero J, Boomsma DI, Bornstein SR, Bovet P, Brambilla

P, Brown MJ, Campbell H, Caulfield MJ, Chakravarti A, Collins R, Collins FS, Crawford DC,

Cupples LA, Danesh J, de Faire U, den Ruijter HM, Erbel R, Erdmann J, Eriksson JG, Farrall M,

Ferrannini E, Ferrières J, Ford I, Forouhi NG, Forrester T, Gansevoort RT, Gejman PV, Gieger C,

Golay A, Gottesman O, Gudnason V, Gyllensten U, Haas DW, Hall AS, Harris TB, Hattersley AT,

Heath AC, Hengstenberg C, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Hovingh GK,

Humphries SE, Hunt SC, Hypponen E, Jacobs KB, Jarvelin MR, Jousilahti P, Jula AM, Kaprio J,

Kastelein JJ, Kayser M, Kee F, Keinanen-Kiukaanniemi SM, Kiemeney LA, Kooner JS,

Kooperberg C, Koskinen S, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C,

Le Marchand L, Lehtimäki T, Lupoli S, Madden PA, Männistö S, Manunta P, Marette A, Matise

TC, McKnight B, Meitinger T, Moll FL, Montgomery GW, Morris AD, Morris AP, Murray JC,

Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Ouwehand WH, Pasterkamp G, Peters A, Pramstaller

PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ritchie M, Rudan I, Salomaa V,

Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Sebert S, Sever P, Shuldiner AR, Sinisalo J,

Steinthorsdottir V, Stolk RP, Tardif JC, Tönjes A, Tremblay A, Tremoli E, Virtamo J, Vohl MC;

Electronic Medical Records and Genomics (eMEMERGEGE) Consortium; MIGen Consortium;

PAGEGE Consortium; LifeLines Cohort Study, Amouyel P, Asselbergs FW, Assimes TL, Bochud

M, Boehm BO, Boerwinkle E, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ,

Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA,

Hamsten A, Hayes MG, Hui J, Hunter DJ, Hveem K, Jukema JW, Kaplan RC, Kivimaki M, Kuh D,

Laakso M, Liu Y, Martin NG, März W, Melbye M, Moebus S, Munroe PB, Njølstad I, Oostra BA,

Palmer CN, Pedersen NL, Perola M, Pérusse L, Peters U, Powell JE, Power C, Quertermous T,

Rauramaa R, Reinmaa E, Ridker PM, Rivadeneira F, Rotter JI, Saaristo TE, Saleheen D,

Schlessinger D, Slagboom PE, Snieder H, Spector TD, Strauch K, Stumvoll M, Tuomilehto J,

Uusitupa M, van der Harst P, Völzke H, Walker M, Wareham NJ, Watkins H, Wichmann HE,

Wilson JF, Zanen P, Deloukas P, Heid IM, Lindgren CM, Mohlke KL, Speliotes EK,

Thorsteinsdottir U, Barroso I, Fox CS, North KE, Strachan DP, Beckmann JS, Berndt SI, Boehnke

M, Borecki IB, McCarthy MI, Metspalu A, Stefansson K, Uitterlinden AG, van Duijn CM, Franke

L, Willer CJ, Price AL, Lettre G, Loos RJ, Weedon MN, Ingelsson E, O'Connell JR, Abecasis GR,

Chasman DI, Goddard ME, Visscher PM, Hirschhorn JN, Frayling TM.

Nat Genet. 2014 Nov;46(11):1173-86. doi: 10.1038/ng.3097. Epub 2014 Oct 5

2015

187. Hemodynamic predictors of long term survival in end stage cystic fibrosis.

Scarsini R, Prioli MA, Milano EG, Castellani C, Pesarini G, Assael BM, Vassanelli C, Ribichini

FL.

Int J Cardiol. 2015 Sep 12;202:221-225. doi: 10.1016/j.ijcard.2015.09.009. [Epub ahead of print]

188. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group.

Burzotta F, Trani C, Doshi SN, Townend J, van Geuns RJ, Hunziker P, Schieffer B, Karatolios K,

Møller JE, Ribichini FL, Schäfer A, Henriques JP.

Int J Cardiol. 2015 Jul 30;201:684-691. doi: 10.1016/j.ijcard.2015.07.065. [Epub ahead of print]

Review.

189. Tpeak-to-Tend/QT is an independent predictor of early ventricular arrhythmias and arrhythmic death in anterior ST elevation myocardial infarction patients.

Mugnai G, Benfari G, Fede A, Rossi A, Chierchia GB, Vassanelli F, Menegatti G, Ribichini FL.

Eur Heart J Acute Cardiovasc Care. 2015 Jul 30. pii: 2048872615598616. [Epub ahead of print]

190. Stent Type and Risk of Late Cerebral Events After Carotid Artery Stenting.

Pacchioni A, Ribichini F , Reimers B.

J Am Coll Cardiol. 2015 Jul 28;66(4):490. doi: 10.1016/j.jacc.2015.04.074. No abstract available.

191. How should I treat an acute anterior myocardial infarction associated with a myocardial rupture? Between the devil and the deep blue sea.

Amabile N, Pascal J, Rohnean A, Raoux F, Nottin R, Caussin C, Vrints CJ, Ribichini FL.

EuroIntervention. 2015 Jun 22;11(2):e1-7. doi: 10.4244/EIJV11I2A46. No abstract available.

192. iFR-FFR comparison in daily practice: a single-center, prospective, online assessment.

Fede A, Zivelonghi C, Benfari G, Pesarini G, Pighi M, Ferrara A, Piccoli A, Ariotti S, Ferrero V,

Mura DD, Battistoni M, Vassanelli C, Ribichini F .

J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):625-31. doi: 10.2459/JCM. 0000000000000 272.

193. European expert consensus on rotational atherectomy.

Barbato E, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, Khashaba A, Koch K, Meyer-Gessner

M, Palazuelos J, Reczuch K, Ribichini FL, Sharma S, Sipötz J, Sjögren I, Suetsch G, Szabó G,

Valdés-Chávarri M, Vaquerizo B, Wijns W, Windecker S, de Belder A, Valgimigli M, Byrne RA,

Colombo A, Di Mario C, Latib A, Hamm C.

EuroIntervention. 2015 May;11(1):30-6. doi: 10.4244/EIJV11I1A6.

194. Position paper on the theoretical basis, practical application and health economic evaluation of the functional assessment of coronary lesions endorsed by the Italian Society of Invasive

Cardiology (SICI-GISE)

Bedogni F, Indolfi C, Ribichini F , Verna E, Leone AM, Polimeni A, Bollati M, Biondi-Zoccai G,

Testa L, Berti S; Italian Society of Invasive Cardiology (SICI-GISE).

G Ital Cardiol (Rome). 2015 Feb;16(2):116-28. doi: 10.1714/1798.19590. Italian.

195. Bypass surgery versus percutaneous coronary intervention: evidence, indications and patient preference according to the latest European guidelines on myocardial revascularization

Ribichini F , Pighi M, Vassanelli C.

G Ital Cardiol (Rome). 2015 Feb;16(2):71-6. doi: 10.1714/1798.19574. Italian. No abstract

available.

196 Genetic studies of body mass index yield new insights for obesity biology.

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich

ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J,

Mägi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J,

Zhao W, Chen J, Fehrmann R, Hedman ÅK, Karjalainen J, Schmidt EM, Absher D, Amin N,

Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret

GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME,

Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE,

Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stančáková

A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J,

Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Ärnlöv J, Arscott

GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R,

Blüher M, Böhringer S, Bonnycastle LL, Böttcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida

Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, Doney AS, Eklund N,

Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS,

Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Gräßler J,

Grönberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen

M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL,

Jeff JM, Johansson Å, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W,

Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindström J, Sin Lo K, Lobbens S,

Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL, McLachlan S, Menni C,

Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Müller G,

Müller-Nurasyid M, Musk AW, Nagaraja R, Nöthen MM, Nolte IM, Pilz S, Rayner NW, Renstrom

F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S,

Schumacher FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV,

Steinthorsdottir V, Stirrups K, Stringham HM, Sundström J, Swertz MA, Swift AJ, Syvänen AC,

Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC,

Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN,

Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q;

LifeLines Cohort Study, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda

A, Gådin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson

S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL,

Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JR,

Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, Van't

Hooft FM, Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT; ADIPOGen Consortium;

AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium;

GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE

Consortium; ReproGen Consortium; GENIE Consortium; International Endogene Consortium,

Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H,

Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC,

Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J,

Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrières J, Ford I, Forouhi NG, Forrester T, Franco

OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS,

Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh

GK, Humphries SE, Hunt SC, Hyppönen E, Illig T, Jacobs KB, Jarvelin MR, Jöckel KH, Johansen

B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinanen-Kiukaanniemi SM,

Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J,

Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Männistö S, Marette A,

Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M,

Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden JF, Peters A, Postma DS,

Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD,

Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz

PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tönjes A, Trégouët DA, Tremblay A,

Tremoli E, Virtamo J, Vohl MC, Völker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC,

Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E,

Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de

Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A,

Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, März

W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njølstad I, Oostra BA, Palmer CN, Pedersen

NL, Perola M, Pérusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo

TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD,

Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P,

Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen

P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn

CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ,

Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E,

Hirschhorn JN, Loos RJ, Speliotes EK.

Nature. 2015 Feb 12;518(7538):197-206. doi: 10.1038/Nature14177. PMID: 25673413

197. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study design and rationale.

Testa L, Biondi Zoccai G, Tomai F, Ribichini F , Indolfi C, Tamburino C, Bartorelli A, Petronio

AS, Bedogni F, De Carlo M.

J Cardiovasc Med (Hagerstown). 2015 Mar;16(3):253-8. doi: 10.2459/JCM. 0000000000000 219.

198. Tamburino C, Barbanti M, D'Errigo P, Ranucci M, Onorati F, Covello RD, Santini F, Rosato

S, Santoro G, Fusco D, Grossi C, Seccareccia F; OBSERVANT Research Group. 1-Year Outcomes

After Transfemoral Transcatheter or Surgical Aortic Valve Replacement: Results From the Italian

OBSERVANT Study.

J Am Coll Cardiol. 2015 Aug 18;66(7):804-12. doi: 10.1016/j.jacc.2015.06.013.

I am Associate Professor of Cardiovascular Medicine at the

Prof. Flavio Luciano Ribichini

Curriculum vitae:

Scientific, teaching and clinical activity.

December 2015

Related documents

Products

Support

I am Associate Professor of Cardiovascular Medicine at the

Prof. Flavio Luciano Ribichini

Curriculum vitae:

Scientific, teaching and clinical activity.

December 2015

Related documents

Add this document to collection(s)

Add this document to saved

Suggest us how to improve StudyLib